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Abstract 
Background Motor Vehicle Crashes (MVCs) are a major cause of morbidity and 
mortality worldwide. This thesis explores the potential use of large databases of 
primary care medical records to investigate the epidemiology of MVCs in the 
United Kingdom and to supplement the data available from national statistics, 
which are believed to understate both the number of crashes, and the number 
of injuries which occur as a result.  
Methods Details of all individuals enrolled in The Health Improvement 
Network (THIN) database whose primary care records indicated involvement in 
a MVC were used to calculate a series of summary measures describing the 
burden and consequences of MVCs. These were compared with data available 
from police accident reports and from hospital admissions.  Data from THIN 
were used to conduct a series of studies of the impact of health and healthcare-
related factors on the risk of involvement in MVCs. Specifically: a case-control 
study of the impact of modifiable lifestyle factors on the risk of MVC; case-
crossover and self-controlled case-series studies of the effect of exposure to 
prescribed medications on the risk of MVC; a case-control study investigating 
the impact of disordered sleep on the risk of MVC; a case-control study of the  
risk of involvement in MVC among individuals with diabetes relative to the 
general population; and; a cohort study assessing whether there is evidence to 
suggest that involvement in a MVC may indicate the presence of undiagnosed 
disease which may impair driving performance. 
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Results  The socio-demographic characteristics of individuals 
involved in MVCs recorded in THIN differ markedly from those recorded in 
police accident reports and hospital admissions data. There was no evidence of 
consistent trends in MVC incidence over time in the three data sources. 
Differences in data collection methodology and the severity and scope of 
crashes recorded may account for these variations. Evidence was found of an 
association between having a high Body Mass Index and involvement in MVCs, 
and between past (but not current) smoking and involvement in MVCs, however 
the recording of data on lifestyle-related exposures such as smoking and alcohol 
consumption in the age-groups  most likely to be involved in MVCs was poor, 
complicating interpretation of these results. Current exposure to 
benzodiazepines and preparations containing opioid analgesics was found to 
increase the risk of involvement in MVCs, as was longer-term use of non-
benzodiazepine hypnotics, selective serotonin reuptake inhibitors and 
antihistamines. No increased risk of MVC was observed with exposure to beta-
blockers or tricyclic antidepressants. Individuals reporting insomnia or snoring 
to their primary care practitioner were found to be at increased risk of MVC, as 
were individuals with diagnosed sleep apnoea. This association was 
independent the use of sedative or antidepressant medications. Individuals 
with diabetes were not found to be at an increased risk of MVC compared with 
the general population, and there was no difference in risk between those 
receiving different forms of treatment. Involvement in a MVC was associated 
with an increased risk of being diagnosed with cardiac disease in the two years 
following the crash. 
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Conclusions  Current sources of data about MVCs in the UK use different 
data collection methodologies, none of which is likely to accurately describe the 
overall burden of MVCs in the population. Primary care data remain a useful 
resource for those wishing to study the epidemiology of MVCs, but care must be 
taken to ensure that the uses to which the data are put are appropriate. Studies 
investigating lifestyle-related exposures are unlikely to produce reliable results 
as primary care recording of such factors is poor in the age-groups most likely 
to be involved in MVCs. Primary care data are more useful when studying the 
time course of pharmacological effects, or the effects of diagnosed illness, and 
can successfully detect previously observed associations. Primary care data is 
currently of little use in the study of injuries associated with involvement in 
MVCs as it is rare for both an injury and its proximate cause to be recorded. The 
investigation of methods by which this problem might be resolved is an 
important avenue for future research.  
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1. INTRODUCTION 
 2 
 
Overview 
Motor vehicle crashes are a leading cause of mortality and morbidity 
worldwide. The World Health Organization estimates that in 2002, road traffic 
injuries accounted for 2.1% of all global deaths, killing approximately 1.2 
million people and injuring between 20 and 50 million more. Road traffic 
injuries were the leading cause of injury mortality worldwide, and the 11th 
leading cause of overall global mortality (at approximately 19.0 deaths per 
100,000 population) (1). The United Kingdom Department for Transport (DfT) 
reports that, in 2005, 3,201 people were killed in motor vehicle crashes in the 
UK and a further 271,017 were injured. Motor vehicle crashes also represent a 
considerable economic burden: the estimated total value of prevention of road 
traffic injuries in 2005 was estimated to be £12.8bn, corresponding to an 
average of £44,930 per casualty (2). A further £5bn was associated with non-
injury costs (such as damage to property and police and insurance 
administration). 
DfT statistics are based entirely on police-reported accidents. Police officers in 
the UK are required to complete a Road Accident Report Form (form STATS19) 
(3) ǲinvolving human death or personal injury occurring on the 
Highway and notified to the police within 30 days of occurrence, and in which one 
    ǳ (defined in the accompanying instructions). In 
practice, it is recognised that there is significant under-reporting (4). This is 
thought to be due to a combination of ignorance of the legal obligation of 
members of the public to report such accidents to the police, the unwillingness 
of intoxicated or unlicensed drivers to involve the police, and the fact that 
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injuries resulting from involvement in a reportable accident may not be 
immediately apparent. A 2006 DfT report investigating the impact of such 
factors on reporting of MVCs found that published studies comparing police and 
hospital records estimated that between 28% and 50% of casualties were not 
reported to the police (4). 
The same report compared specific hospital records from the Gloucester Royal 
Hospital with local police accident reports and found that in the years 1996 to 
2000, between 42% and 48% of accidents were not reported to the police. 
Furthermore, it was found that 50% of minor injuries and 38% of serious 
injuries recorded by the police could not be identified in the hospital records. 
This suggests that a large proportion of those injured in accidents seek 
treatment elsewhere Ȃ perhaps from their General Practitioner (GP) Ȃ or do not 
sustain injuries serious enough to require medical attention.  Given that 
hospital data were found to omit casualties recorded by the police and vice 
versa, it seems likely that there are a further group of casualties unrecorded by 
both. 
On the basis of this evidence it can reasonably be concluded that the official UK 
figures considerably underestimate the true overall human and financial costs 
of road traffic accidents in the United Kingdom. It is clear, then, that there is a 
need to investigate alternate sources of data which may be used (or combined 
with existing sources) to produce more robust measures of the burden of road 
traffic accidents in the United Kingdom. 
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One possible source of such data is the primary care medical record. In the 
United Kingdom National Health Service (NHS), General Practitioners occupy a ǲǳ           -
emergency patients requiring advice or treatment. The GP is responsible for 
treating minor injuries and ailments and for the routine management of chronic 
conditions. Patients are referred onward to specialist secondary care 
practitioners for further investigations or for specialist treatments where 
necessary. Secondary care institutions routinely send back summaries of the 
investigations undertaken and treatments given along with details of any     ǯ   Ǥ  
present directly to secondary care institutions (for instance at Accident & 
Emergency Departments) are normally asked to give the contact details of their 
GP in order that they may be notified of the reason for attendance, and the     Ǥ  ǯ    
contain a comprehensive summary of their medical history and their use of NHS 
services. 
In recent years, there has been a drive to computerise the storage and 
maintenance of medical records, culminating in the ongoing NHS national 
programme for IT, which is intended to eventually provide a centralised, 
nationally networked, records storage system allowing detailed patient 
information to be accessed and updated by practitioners throughout the NHS. 
Whilst this work has yet to be completed, mature computerised practice 
management systems have been available in primary care settings for many 
years, simplifying the management of large practices and to reducing the need 
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to safely store and maintain large quantities of paper-based records, This has 
led to the creation of research databases which aggregate data extracted from 
the medical records storage systems at large numbers of primary care practices. 
These databases contain vast quantities of prospectively collected medical and 
lifestyle data for millions of people around the UK and are of tremendous value 
in the field of epidemiological research, allowing large-scale observational 
studies to be conducted without the need for time-consuming and expensive 
data collection. 
The use of such primary care databases offers a number of potential benefits to 
the field of road safety research. The large samples of the UK population for 
whom data are available may permit the calculation of far more inclusive 
estimates of the burden of road traffic accidents in the UK. Furthermore, the 
availability of data on many clinically relevant lifestyle factors, as well as on 
medical treatments and diagnoses permits the study of their impact on the risk 
of involvement in MVCs. This thesis uses data from The Health Improvement 
Network (THIN), one such database, to describe the recording of road traffic 
accidents in primary care records and to examine the effects of a number of 
lifestyle and healthcare related factors on the risk of road traffic accident. 
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The Health Improvement Network 
Data Collection 
The Health Improvement Network (THIN) is a large database of primary care 
records from General Practices around the United Kingdom. THIN data may be 
divided into three broad classes Ȃ vision data, other computerised data and 
historical data. Vision data are extracted from the Vision patient management 
system, a software package produced by In Practice Systems (London, UK), 
which is used to electronically store patient records at all participating 
practices. Patient records (stripped of identifying details) are extracted on a 
regular basis by means of a secure internet connection and collected by EPIC  
(London, UK), the company responsible for assimilating the raw data into the 
final THIN database. Vision data contain basic demographic details of all 
currently and previously registered patients, all diagnoses and clinically 
relevant recordings made by (or reported to) the practitioner, all prescriptions 
issued and in more recent records, details of tests ordered (and the results), 
details of occupation and information regarding a range of lifestyle factors 
which may affect health.  
Practices are recruited via the partnership between EPIC and In Practice 
Systems, and are paid for the use of their data. In order to join THIN, each 
practice must meet minimum quality control standards for data entry as laid 
down by EPIC. These standards are regularly updated to reflect changes in NHS 
requirements for data collection and storage. The recording of information 
relating to a series of key conditions and exposures is regularly audited to 
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ǯǤ
is cause for concern about the quality of recording in a particular practice, that 
practice may be suspended from the database until the problem is corrected or 
removed altogether if issues persist. 
Where practices have used other computerised patient management or 
prescribing systems prior to the installation of Vision, other computerised data 
may be available. The quality and scope of this data varies according to the 
system previously in use and the ease with which records may be converted 
and transferred to Vision. Historical data, derived from paper records or 
entered in the course of routine care, may also be present. These data are of 
somewhat limited use as not all practices choose to systematically transfer 
older, paper-based records into Vision, introducing a risk of bias. Such 
information may be omitted altogether, may only be present for currently 
registered patients, or may include only those diagnoses and events considered ǯǤ 
A number of different iterations of THIN are available, reflecting different stages   ǯ Ǥ       
number of participating practices at the time of data assimilation. For example, 
THIN 255 contains data from 255 practices throughout the UK. Within each 
major version, there may be a number of sub-versions relating arising from 
periodic updates to the collected data. For example, THIN 255 (November 
2004) contains data from 255 practices, where the latest date of data extraction 
was in November 2004. 
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THIN data are supplied in the form of five tables; the patient table, the medical 
table, the therapy table, the additional health details (AHD) table and the 
postcode variable indicators (PVI) table. Each row of each table contains a 
unique practice identification code and a unique (per practice) patient 
identification code, which together form a unique identifier for individuals 
within the database. It should be noted that there is currently no mechanism by 
which patients transferring from one THIN practice to another may be tracked, 
so certain individuals may appear multiple times within the database. This is 
not a major concern when carrying out analyses dealing exclusively with data 
relating to incident events and diagnoses, but may complicate the interpretation 
of historical data. 
Data Format 
The patient table (Table 1) contains basic demographic and registration details 
about each patient, including (where applicable) the practiceA and patientB 
identifiers, year of birthD (and month, for patients aged 16 or younger), sexF, a 
unique (per practice) household identifierE, date of registrationG, a code 
indicating registration statusH (e.g. active, inactive, transferred out) date of 
transfer out of practiceI, a code indicating the reason for registration or 
transferJ, date of deathK, the date of practice computerisationL, the date of 
introduction of Vision at the practiceM, the date of last data collection from the 
practiceN and a quality-control flag indicating the integrity of the data for that 
patientC (a minority of patient records exhibit problems with the dating of 
entries, such as consultations recorded after death, death or transfer dates 
earlier than registration date, long periods without any data recording, which 
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are identified by this flag, allowing researchers to decide to include or exclude 
them from study as appropriate to the investigation in question). It is important 
to note that household identifiers relate to individual addresses, rather than 
dwellings. Individuals living in different flats or apartments within the same 
building may therefore have the same household identifier, despite not forming 
part of the same household. The date of computerisation is the date from which 
the practice began routinely issuing prescriptions using Vision or a previously 
installed system.  
Table 1: Sample extract from the patient table 
 
The medical table (Table 2) contains details of each observation or diagnosis 
made by, or reported to the general practitioner. Records are classified using 
Read Clinical Terms (5), a coded, hierarchical list of terms used in medical 
records. Practitioners can search the Read Term list within Vision using 
keywords and attach appropriate codes to each consultation record. In addition, 
some codes are generated automatically by Vision when practitioners use 
specialised data collection dialogs to record information about certain 
exposures and conditions (for example, Vision has a specialised dialog for 
prac
A
patid
B
patflag
C
yobstring
D
famnum
E
gender
F
regreal
G
regstat
H
xferreal
I
regrea
J
deathreal
K
compdate
L
visdate
M
lastdate
N
a1234 02Gh A 19710000 12317 1 19761201 2 0 19980901 19992804 20041102
a1234 02Dy A 19740000 12183 2 19761202 2 0 19980901 19992804 20041102
a1234 02CG A 19680000 12091 1 19761203 5 20030114 30 19980901 19992804 20041102
a1234 02LS A 19630000 12552 1 19761204 2 20031209 99 20031209 19980901 19992804 20041102
a1234 005i A 19670000 2865 2 19761205 2 19980901 19992804 20041102
a1234 001F A 19460000 587 2 19761206 5 19980901 19992804 20041102
a1234 001Q A 19720000 587 1 19761207 5 19980901 19992804 20041102
a1234 001W A 19640000 4167 1 19761208 2 19980901 19992804 20041102
a1234 00?M A 19430000 1463 2 19761209 2 19980901 19992804 20041102
a1234 00@S A 19460000 1527 1 19761210 2 19980901 19992804 20041102
a1234 00?I A 19280000 2344 2 19761211 2 19980901 19992804 20041102
a1234 00aM A 19610000 3889 1 19761212 2 19980901 19992804 20041102
a1234 00aW A 19760000 880 2 19761213 5 19980901 19992804 20041102
a1234 00AY A 19740000 4520 2 19761214 2 19980901 19992804 20041102
a1234 00B0 A 19720000 3695 1 19761215 2 19980901 19992804 20041102
a1234 00b2 A 19640000 3303 1 19761216 5 19980901 19992804 20041102
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recording information about height, weight and body mass). The codes entered 
for each patient form the basis of the medical table. Each row of the table 
contains the practiceA and patientB identifiers, a record quality indicatorE, a 
Read Term codeD and an associated dateC. The table contains one row per Read 
Term. Each consultation may therefore result in the addition of multiple rows of 
data. 
Table 2: Sample extract from the medical table 
 
By default, Vision applies the current date to any new entries made in a ǯǤ
of entry, it is necessary to change adjust the date manually. In practice, this is 
not always done. The date of any recording in the medical table may reflect 
either the date of entry or the date on which the observation was made. Dates of 
medical recordings may not, therefore, always be accurate. A study of data entry 
patterns in the General Practice Research Database (GPRD), the forerunner of 
THIN, found that the numbers of diagnoses apparently made in the first year 
prac
A
patid
B
evdate
C
medcode
D
medflag
E
source
F
episode
G
nhsspec
H
locate
I
a1234 a123 20020300 G55..00 R 0 4 0 I
a1234 a123 19761001 7E04900 R 0 4 0 O
a1234 a123 19890601 7D19400 R 0 4 0 O
a1234 a123 19910410 K510200 R 0 4 0 O
a1234 a123 19980304 5372.00 R 0 4 0 O
a1234 a123 19990611 T1...00 R 0 4 0 I
a1234 a123 19991109 424..00 R 0 4 0 I
a1234 a123 20000118 7L17.00 R 0 4 0 A
a1234 a123 20000411 7L17.00 R 0 4 0 I
a1234 a123 20000518 7L17.00 R 0 4 0 A
a1234 a123 20000804 863..12 R 0 4 0 I
a1234 a123 20001121 G730.00 R 0 4 0 A
a1234 a123 20010115 9N1S.00 R 0 4 0 N
a1234 a123 20010220 9N1S.00 R 0 4 0 N
a1234 a123 20010622 9N1S.00 R 0 4 0 O
a1234 a123 20011219 1....00 R 0 4 0 I
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after registration are far higher than the numbers made subsequently, 
suggesting that recordings made during this period may reflect back-entry of 
data obtained from previous practitioners or from previous (computerised or 
paper-based)  recording systems, rather than incident events (6). It is important 
to consider this issue when using THIN data for epidemiological studies. 
Each row of the medical table also contains a set of codes indicating the sourceF, 
locationI and specialtyH associated with each recording. Source codes indicate 
whether each observation or diagnosis derives from a consultation, a telephone 
conversation, a letter received by the GP (or a number of other possibilities). 
Location codes indicate where the observation or diagnosis was made (e.g. ǡǯǡȌ
codes indicate the medical specialty of the individual or service responsible (e.g. 
Oncology, renal, respiratory, mental health). Finally, there is code indicating 
whether the recording relates to a new event or an ongoing conditionG. Each of 
these codes is only meaningful if the data are correctly entered into Vision, and 
may not be available where recordings derive from earlier computer systems. 
Their usefulness may therefore be somewhat limited. 
The therapy table (Table 3) contains details of all prescriptions issued to each 
patient by the practitioner. Each row of the table contains the practiceA and 
patientB identifiers, a quality control flagE and a multilexD code which uniquely 
identifies the preparation prescribed, the unit dose and the number of doses per 
packet. Vision, in common with some other systems previously in use at 
participating practices, is capable of producing printed prescriptions. 
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Preparations can be selected from a searchable list, and directions and 
quantities can be entered either through the prescribing interface or as free 
text. Where quantities and directions are entered through the interface, or the 
free text can be decoded automatically by EPIC, a series of codes are available 
describing the quantity prescribedG, the daily unit dosageM (e.g. number of 
tablets, measures or injections) the length of prescriptionH (i.e. number of days 
treatment) and the directions for useF (e.g. 3 times a day, with food, on an 
empty stomach). Each row also contains the date of prescriptionC, which is 
likely to be more accurate than the dates of other recordings in THIN owing to 
the convenience of using Vision to print prescriptions. 
Table 3: Sample extract from the therapy table 
 
The therapy table also contains a code indicating whether the prescription is 
novel, or part of an ongoing course of treatmentI. Where the prescription is 
repeated, another code represents the number of times, in total, that the 
prescription has been issuedK. Where preparations may be considered harmful 
or addictive in prolonged use, another code may be present indicating the 
maximum number of times the prescription may be issuedL. These codes may 
prac
A
patid
B
rxdate
C
drugcode
D
therflag
E
doscode
F
rxqty
G
rxdays
H
rxtype
I
opno
J
seqnoiss
K
maxnoiss
L
dosgval
M
a1234 ab12 19920107 97130998 Y 16 20 0 1 0 0 0 -1
a1234 ab12 19920902 97464998 Y 1 6 0 1 0 0 0 -1
a1234 ab12 19940113 97464998 Y 1 3 0 1 0 0 0 -1
a1234 ab12 19941228 97110997 Y 16 20 0 1 0 0 0 -1
a1234 ab12 19980806 94851997 Y 8 20 0 1 0 0 0 -1
a1234 ab12 19991110 93304998 Y 55 90 0 1 0 0 0 -1
a1234 ab12 20010619 93304998 Y 139 90 0 1 0 0 0 2
a1234 ab12 20011204 97110997 Y 48 20 0 1 0 0 0 4
a1234 ab12 20021113 98617998 Y 963 13 0 1 0 0 0 3
a1234 ab12 20040726 96974998 Y 1GZz 25 0 1 0 0 0 -1
a1234 c345 19990823 96379998 Y 4943 30 0 0 0 1 3 3
a1234 c345 19990923 97227998 Y 03mW 28 0 0 0 1 4 -1
a1234 c345 19990927 97227998 Y 03ns 84 0 0 0 1 84 -1
a1234 c345 19991007 96379998 Y 958 21 0 0 0 3 4 3
a1234 c345 19991014 97227998 Y 03mg 28 0 0 0 4 4 -1
a1234 c345 19991028 96379998 Y 743 21 0 0 0 2 4 3
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not always be reliable, as they depend on each subsequent prescription being 
issued specifically as a repeat in Vision. Where a prescription is only slightly 
modified (e.g. from one brand name to another), or an identical prescription is 
written afresh within Vision, the counter is reset and must be manually changed 
to reflect the true issue number. A final code indicates the identity of the 
practitioner responsible for issuing the prescriptionJ. 
The AHD table (Table 4) is perhaps the most complicated of the THIN data 
tables. It is used to hold recordings which necessarily comprise multiple pieces 
of information; typically, measurements, test results, quantities and death 
certification data.  Each row contains patientA and practiceB identifiers, a 
quality-control indicatorE, an AHD codeD indicating the record type, an 
associated Read Term codeH, a record dateC, and one or two AHD valuesF,G 
which contain explanatory data. The AHD table may be used to store 
measurements, in which case the first AHD value may indicate the units of 
measurement, and the second the measurement itself. Where an AHD record 
contains the result of a biochemical test, the values might relate to the unit of 
measurement and the measurement, or the measurement and the 
interpretation (e.g. normal/abnormal). The associated Read Terms may add 
contextual information to the record; for example, an AHD record for tobacco 
consumption might carry a Read Term indicating whether the recorded daily 
quantity relates to cigarettes or cigars, or whether the record relates to current 
or past tobacco consumption. 
 14 
 
Table 4: Sample extract from the additional health details (AHD) table 
 
Dates within the AHD table are subject to the same type of uncertainty as those 
within the medical table. For example, details of height, weight and tobacco and 
alcohol consumption might be collected on a form at the time of registration, 
but not entered until later. The date in the AHD record might reflect either the 
date that the form was completed, or the date on which the data were entered 
into the computer. The AHD table also contains details of the locationI and 
specialtyJ associated with each record. These are subject to similar concerns to 
their medical table equivalents. 
The PVI table (Table 5) contains information about the sub-postcode area (e.g. 
NG5-5 for NG5 5UE) in which each patient lives. Each line contains practiceA 
and patientB identifiers, a 6-level indicator of building densityC (e.g. 1=urban, 
6=rural), a set of valuesD-H indicating the ethnicity of the local population (e.f. if 
percwD=1, the postcode falls into the quintile of national postcodes with the 
lowest proportion of white residents), a variable indicating the quintile of 
prac
A
patid
B
evdate
C
ahdcode
D
ahdflag
E
ahdval1
F
ahdval2
G
medcode
H
nhsspec
I
locate
J
a1234 01ab 19940512 1003050000 R 0 0 1362.12 0 I
a1234 01ab 19960801 1003040000 R 0 0 137L.00 0 I
a1234 01ab 19990525 1002000010 R 4000 0 6584.00 0 O
a1234 01ab 20010914 1005010500 R 134 80 246..00 0 I
a1234 02cd 19921014 1003040000 R 0 0 137L.00 0 I
a1234 02cd 19930825 1005010200 R 56 23.3 22A..00 0 I
a1234 02cd 19950221 1005010500 R 128 74 246..00 0 I
a1234 02cd 19951011 1002550000 R 0 0 61L..00 0 I
a1234 02cd 20001220 1052000000 R N 0 9N7..11 0 I
a1234 02cd 20020328 1001400152 R 0 0 4672.00 0 I
a1234 02cd 20020328 1005010200 R 59 24.5 22A..00 0 I
a1234 02cd 20020402 1001400289 R 0 0 4J...00 0 P
a1234 02cd 20030801 1005010200 R 59 24.5 22A..00 0 I
a1234 01AA 19960219 1002000001 R 4000 0 6564.00 0 I
a1234 01AA 19960219 1005010500 R 190 100 246..00 0 I
a1234 01AA 19991130 1005010100 R 1.67 0 229..00 0 I
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postcodes with ascending levels of limiting long term illness among the local 
populationI, a set of values indicating levels of air pollution (quintiles of 
postcodes with ascending levels of nitrogen dioxideJ, particulate matterK, 
sulphur dioxideL and nitrous oxidesM), a value indicating into which quintile of 
postcodes with ascending levels of deprivation (as measured by Townsend 
Index (7) ) the area fallsN, and the date on which the information was last 
updatedO. All the variables are based on 2001 classifications. 
Table 5: Sample extract from the postcode variable indicators (PVI) table 
 
The THIN Population 
The earliest recordings in THIN date back to the first quarter of the 20th 
century. As discussed previously, such data are of limited value; of far greater 
importance are those recordings made after the introduction of computerised 
patient management systems. The earliest computerised data available in THIN 
255 (November 2004), the version used for much of this project, date back to 
1985. The amount of data available from this time is small, as only one 
participating practice had a computerised data-collection system in place at this 
prac
A
patid
B
urbanrural
C
percw
D
percm
E
percas
F
bercb
G
perco
H
llti
I
no211
J
pm1012
K
so2
L
nox
M
townsend
N
date
O
a1234 abc0 5 1 5 5 5 5 2 4 4 3 4 5 20060330
a1234 abc1 5 1 5 5 5 5 2 4 4 3 4 5 20060330
a1234 abc2 5 1 5 5 5 5 2 4 4 3 4 5 20060330
a1234 abc3 5 1 5 5 5 5 2 4 4 3 4 5 20060330
a1234 abc4 5 1 5 5 5 5 2 4 4 3 4 5 20060330
a1234 abc5 5 1 5 5 5 5 2 4 4 3 4 5 20060330
a1234 abc6 5 1 5 5 5 5 2 4 4 3 4 5 20060330
a1234 abc7 5 1 5 5 5 5 2 4 4 3 4 3 20060330
a1234 abc8 5 1 5 5 5 5 2 4 4 3 4 3 20060330
a1234 abc9 5 1 5 5 5 5 2 4 4 3 4 4 20060330
a1234 abc9 5 1 5 5 5 5 2 4 4 3 4 4 20060330
a1234 abca 5 1 5 5 5 5 2 4 4 3 4 4 20060330
a1234 abcb 5 1 5 5 5 5 2 4 4 3 4 4 20060330
a1234 abcc 5 1 5 5 5 5 2 4 4 3 4 4 20060330
a1234 abcd 5 1 5 5 5 5 2 4 4 3 4 4 20060330
a1234 abce 4 1 5 5 5 5 2 5 4 4 5 3 20060330
a1234 abcf 5 1 5 5 5 5 2 4 4 3 4 2 20060330
a1234 abcg 4 1 5 5 5 5 2 5 4 4 5 3 20060330
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time. Figure 1 shows the increase in the available follow-up in each subsequent 
year. 
Figure 1: Availability of computerised follow-up data in THIN 255 (November 
2004), by year of collection 
 
The available data increase steadily with each subsequent year of collection, 
reaching a plateau in the year 2000. A similar pattern is observed in later major 
versions of THIN (THIN 300 and THIN 314) as most practices nationwide had 
(THIN compatible) computerised data recording systems in place by this time. 
Data for the year 2004 are not presented here as they are incomplete in this 
revision of THIN-255.  
Figure 2 shows the equivalent graph for data collected using the Vision system. 
The plateau occurs much later (2002) in these data. This is due to practices 
switching from other systems to Vision. The plateau occurs later in each 
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subsequent major version of THIN for the same reason. The plateau typically 
occurs approximately two years before the date of  first release of each major 
version as EPIC stipulate that Vision must have been in productive use for more 
than one year  before a practice may join THIN. Once again, data from the year 
2004 are excluded as they are incomplete in this revision. 
Figure 2: Availability of follow-up data collected using Vision in THIN 255 
(November 2004), by year of collection 
 
Table 6 shows the composition of the 2003 THIN-255 (November 2004) 
population and the 2003 United Kingdom general population broken down by 
age and sex. The age structure of both populations is approximately vertical up 
to age 59, with a slow decline thereafter.  There are approximately equal 
proportions of males and females within each population up to age 69, with a 
decline in the proportion of males thereafter (due to the greater longevity of 
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women in general). There is minimal difference in the observed proportions 
between data derived from Vision, and the combined computerised data. Some 
slight differences exist between the structures of the THIN population(s) and 
the general population, but these are very small. Overall, it can be concluded 
that the THIN population reflects closely the age-structure of the United 
Kingdom population. 
Table 6: Comparison between THIN 255 (November 2004) population and the 
United Kingdom population by age and sex, 2003 
 
Figure 3 shows the proportions of the THIN population living in postcode which 
fall into each quintile of deprivation (as measured by Townsend Index) and 
local area ethnicity. In a completely nationally representative population the 
lower 5 segments of each column would be expected to be of equal size. This is 
not the case in the THIN population Ȃ the graph suggests that whilst the 
proportions falling into the mid-quintiles are similar, the most deprived quintile 
of the UK population is slightly under-represented in THIN 255, whilst the least 
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deprived quintile is slightly over-represented.  The ethnicity data suggest that 
the white population is substantially under-represented, whilst the ethnic 
minority populations are substantially over-represented, although the large 
proportion of the population for whom ethnicity data are not available (~20%) 
make it difficult to form firm conclusions. 
Figure 3: Proportion of THIN 255 (November 2004) population living in postcode 
areas falling into UK national quintiles of deprivation and ethnicity 
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Aims and Objectives 
The specific aims and objectives of this thesis are: 
x To use data from The Health Improvement Network to describe the 
incidence and severity of motor vehicle crashes in the United Kingdom, 
stratified by socio-demographic group. 
x To compare the estimates obtained using THIN data with those available 
from police accident reports and from hospital reports. 
x To use data from THIN to investigate the effect of modifiable lifestyle 
factors on the risk of involvement in MVCs. 
x To investigate the effects of taking prescribed medications on the risk of 
involvement in MVCs 
x To explore the impact of diagnosed illnesses on the risk of MVCs and to 
test the hypothesis that involvement in a MVC may predict the 
subsequent development of diseases which may impair driving ability. 
Role of Candidate 
The candidate was provided with an initial extract of THIN data containing the 
records of all individuals involved in an MVC at any time. The candidate carried 
out all analyses, literature reviews and designed all the studies reported in this 
thesis, with assistance from other members of the Division of Epidemiology & 
Public Health as described in Appendix III.  
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2. MOTOR VEHICLE CRASH RECORDING IN THIN
 22 
 
Clinical Coding of Motor Vehicle Crashes in THIN 
The Read Term list contains a large number of terms relating to MVCs. The 
more detailed terms contain information about the type of road user and 
vehicle involved, whether each individual was driving or a passenger (in the 
case of car occupants or motorcyclists) and where they were seated in or on the 
vehicle. The Read Term list was searched to obtain all terms relating to 
accidents involving motor vehicles which have been used in THIN records. The 
list of codes obtained, and the number of recordings associated with them in 
THIN-255 (November 2004) are given in Table 7. In practice, the highly specific 
terms are rarely used (presumably because selecting the correct term can be 
somewhat time-consuming). The vast majority of crashes recorded in THIN are 
descrǲȋȌǳǤ
therefore impossible to determine whether an individual involved in a MVC was 
driving, a passenger, a pedestrian or another road user. This is an important 
limitation of the THIN data. 
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Table 7: Numbers of occurrences of MVC recordings in THIN 255 (November 2004) 
 
A minority of individuals have multiple accidents on record (Table 8). There 
are, however, a number of reasons to suspect that most of these do not truly 
reflect new accidents. Firstly, a large number of these multiple recordings are 
made on the same day as the first accident, or the day after (Figure 4) Ȃ possibly 
due to accidental double entry, or the practitioner using multiple Read Terms to 
describe the circumstances of each accident. Secondly, the majority of these 
subsequent recordings are made in the four weeks immediately after the first 
accident Ȃ it is somewhat implausible that accidents would occur in such quick 
succession. Finally, there are peaks in the number of recordings at weekly 
intervals following the first recording, suggesting that these relate to follow-up 
appointments. 
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Table 8: Numbers of individuals with single and multiple MVC recordings in THIN 
255 (November 2004) 
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Figure 4: Length of interval between first MVC recording and subsequent 
recordings in THIN 255 (November 2004) 
 
As a consequence of these concerns, second and subsequent accident 
recordings are excluded from the analyses in this thesis, in order to avoid 
potential bias due to these spurious multiple recordings.  
Comparison of summary statistics derived from THIN data with other 
UK data sources 
The records of all individuals in THIN-255 (November 2004) with a recorded 
motor vehicle accident were extracted and cleaned. Records with no useable 
date of accident were excluded, as were records where the accident occurred 
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accident occurred prior to the introduction of computerised records at their 
practice. The raw numbers of accident records obtained are given in Table 9. 
The period of computerised follow-up was determined for each patient in the 
complete THIN population. The period was defined as starting on the latest of 
date of birth, date of patient registration and date of practice computerisation 
and as ending on the earliest of date of transfer to another practice, date of 
death and date of last data collection at the relevant practice. This information 
was used to calculate the sex-specific yearly total computerised follow-up (in 
persion-years) available in THIN, using STATA 9 (STATA Corp. TX, USA) for 
Windows XP. Patients whose records were flagged as incomplete or corrupt in 
the patient table were excluded from the calculation. These data were used as 
denominators in order to calculate crude yearly incidence rates of MVCs in 
THIN  (Table 10 & Figure 5). 
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Table 9: Number of recorded MVCs in THIN 255 (November 2004) computerised 
follow-up, by gender (1990 to 2003) 
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Table 10: Incidence rates of MVCs in THIN 255 (November 2004) computerised 
follow-up, by gender (1987 to 2003) 
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Figure 5: Incidence rates of MVCs in THIN 255 (November 2004) computerised 
follow-up, by gender (1990 to 2003) 
 
Table 11  and Figure 6 show the estimated incidence of road traffic accident 
casualties in Great Britain in the same time period. As discussed in the previous 
chapter, these data are based on written police accident reports (which are 
routinely passed to the UK Department for Transport) and therefore represent 
those crashes serious enough to warrant police attendance or which are 
voluntarily reported to the police by those involved. There is no specific 
definition of injury in the guidelines for completion of the STATS 19 accident 
report form; the decision as to whether the injuries sustained by those involved 
in a crash are serious enough to warrant the submission of a report is at the 
discretion of the officer responsible. It remains uncertain whether this results in 
under-reporting of minor injuries or internal injuries which may not be 
immediately apparent. Conversely, very minor contusions may be 
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inappropriately recorded as injuries. It is also unclear whether reporting 
practice may vary between forces or jurisdictions. 
Two things are particularly notable; firstly, the incidence is far higher in the 
national statistics than in the THIN data (suggesting that police data may indeed 
record details of individuals with injuries not serious enough to warrant 
subsequent medical attention). Secondly, the national data show a continual 
declining trend not apparent in the THIN data.  
Table 11: Estimated incidence of MVCs resulting in injury, by gender (police 
reports, Great Britain 1990 to 2003) 
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Figure 6: Estimated incidence of MVCs resulting in injury, by gender (police 
reports, Great Britain 1990 to 2003) 
 
To compare the recorded incidence of MVCs in primary care and police reports 
with data from secondary care, summaries of Hospital Episode Statistics (HES) 
data were obtained from the NHS Information Centre, UK. HES data derive from 
the admission forms and discharge forms (or, in recent years, their 
computerised equivalents) completed by the attending physician for each 
patient admitted as an in-patient to secondary care. The admissions and 
discharge records contain basic demographic details (such as age and sex and 
home postcode) of each patient, the reasons for admission and a brief summary 
of diagnoses made during the stay. HES data will therefore only record the most 
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serious crashes; those resulting in injuries severe enough to warrant in-patient 
admission to hospital. 
 Diagnostic data are recorded in the form of one or more International 
Classification of Diseases (ICD) (8) codes which may be directly selected by the 
physician (in the case of computerised records) or alternatively selected by the 
administrator responsible for compiling data from paper records, based on the ǯǤ The ICD code list was searched for all entries relating to 
MVCs and detailed summaries, broken down by year, age, gender and socio-
economic status were requested from the Information Centre. The estimated 
incidences of MVC-related admissions, by age and gender, in these data are 
given in Table 12 and Figure 7.  
Table 12: Estimated incidence of MVCs resulting in hospital admission, by gender 
(England 1989 - 2003) 
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Figure 7: Estimated incidence of MVCs resulting in hospital admission, by gender 
(England 1989 - 2003) 
 
The incidence of MVCs recorded in the HES data is considerably lower than that 
in both the THIN and the police report data, reflecting the fact that only serious 
injuries require hospitalisation. Similarly, the low incidence in THIN compared 
with the police report data suggest that many injuries recorded by the police 
may be very minor and not require medical attention. An alternative possibility 
is that injuries sustained in MVCs are not always recorded as such by general 
practitioners. Examination of a sample of 100,000 randomly selected patient 
records revealed that over 90% of consultations recorded in THIN carry only 
one Read Term (i.e. a single entry in the medical or AHD table on each unique 
date). It is therefore possible that injuries which require specific treatment may 
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be coded directly, but without an associated MVC-related Read Term. This 
explanation is supported by the low incidence of coded injuries associated with 
MVCs in the THIN population: when the records of all individuals involved in 
MVCs during the computerised follow-up period were searched for Read Terms 
indicating fractures or whiplash injuries within 14 days before and after the 
date of MVC, fewer than 200 such injuries were identified.  
When entering information into Vision (and earlier data-collection systems) 
practitioners have the option of entering supplementary details of a 
consultation in text format. It is not currently possible for researchers to obtain 
full access to these additional data. It is possible, therefore, that injuries 
sustained in MVCs are typically referred to in the text portion of the record, but 
not coded separately (especially if there are multiple injuries). Conversely, it is 
possible that injuries may be coded directly and the cause of the injury (the 
MVC) may be referred to in the text. Depending on whether there is a 
systematic bias towards coding more severe injuries directly (something which 
it is not currently possible to adequately assess), Read Term coded MVCs in 
THIN may represent either a random sample of a greater overall number of 
MVCs reported to primary care practitioners, or may represent mostly 
comparatively minor incidents. This issue, and means by which such 
deficiencies in recording might be addressed, are discussed in greater detail in 
the concluding chapter. 
In common with the THIN data, the HES data do not show the declining trend in 
recent years apparent in the police reports. This suggests that either the 
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proportion of accidents resulting in injuries serious enough to warrant medical 
attention is increasing, or that changes in the quality of MVC recording in one or 
more of these datasets have occurred in recent years. The increase in incidence 
of MVCs recorded in THIN approximately coincides with the introduction of the 
Vision software at participating practices, so it is possible that improvements in 
recording associated with the use of this more advanced system may have 
obscured any true declining trend, although the smaller increase in MVCs 
recorded in HES (a much more stable and longer established reporting system) 
over the same period suggests that this may, at least in part, reflect a true 
increase. 
Figure 8 shows the breakdown of motor vehicle crash incidence rates by age 
and sex in the THIN population in 2003. These follow a similar overall trend to 
the equivalent DfT (Figure 9) and HES (Figure 10) data, rising to a peak by age 
25 and declining steadily thereafter. There are two notable differences Ȃ in the 
police report and HES data, the peak occurs by age 20, and the incidence of road 
traffic injury among males is considerably greater than among females. In the 
THIN data this is reversed, suggesting either that women are more prone to 
accidents of the sort most likely to be recorded in THIN, or that women may be 
more likely to report minor accidents to their GP. 
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Figure 9: MVC incidence by age and sex in the Great Britain population, 2003 
(Source: DfT) 
 
0
200
400
600
800
1000
1200
1400
1600
0 
to
 4
5 
to
 7
8 
to
 1
1
12
 t
o 
15
16
 t
o 
19
20
 t
o 
29
30
 t
o 
39
40
 t
o 
49
50
 t
o 
59
60
 t
o 
69
70
 t
o 
79
80
 t
o 
89
Age group
In
c
id
e
n
c
e
 (
p
e
r 
1
0
0
,0
0
0
)
Males
Females
 38 
 
Figure 10: Incidence of MVCs leading to hospital admission in England by age and 
sex, 2003 (Source: NHS Information centre) 
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of (33 different) metrics describing typical income, employment, housing 
conditions, geographic access to basic amenities, education levels and levels of 
disability in each area. Given that the IMD2000 score incorporates information 
similar to that used to calculate the Townsend Index, it is likely that the two 
measures will be broadly comparable, although the greater range of 
information included in the IMD2000 score may result in important differences 
in quintile-level classification between the two measures. 
The DfT do not provide detailed breakdowns of MVC incidence by socio-
economic status for a police report comparison, but the findings of a  study (10) 
carried out in Lothian for the Scottish Executive, which linked police reports to 
census data, suggest MVC incidence is highest in the most and the least deprived 
groups (a U-shaped distribution).  Neither of the healthcare datasets appears to 
capture this trend, although the population of Lothian may not be 
representative of the UK as a whole, so it is difficult to draw inferences from 
these discrepancies. 
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Figure 11: Breakdown of MVC recordings in THIN 255 by quintile of postcode-level 
Townsend deprivation index, 2003 
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Figure 12: Breakdown of MVCs recorded in Hospital Episode Statistics by quintile 
of Indices of Multiple Deprivation 2000 score, 2003 
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of different areas, may bias the demographic breakdowns of MVC incidence) 
and upon police priorities at the time it occurred. Data from general practice 
may provide a more consistent definition of MVCs over time and in different 
areas, but are effectively dependent on self-reporting are therefore likely to 
over-represent those groups most likely (or most easily able) to consult their 
GP. Data from Hospital Episode Statistics are the least likely to be affected by 
such biases as (a physician assessed) injury serious enough to warrant 
admission to hospital must be sustained for an individual to appear in these 
data, but consequently exclude information about the vast majority of 
individuals injured in less serious MVCs. None of these three data sources is 
likely to provide an accurate description of the overall burden of MVCs, or of 
trends over time. An additional problem, especially when attempting to 
investigate factors which affect the probability of involvement in a MVC, is that 
none of the three data sources reliably differentiate between drivers, 
passengers and other road users.  
Whilst the comparisons between MVC recording in THIN and other data sources 
tend to suggest that neither is suitable for monitoring the incidence of MVCs, it 
is important to note that this does not preclude the use of THIN data to assess 
which factors may affect the risk of MVC. Such assessments depend entirely on 
the adequacy of the comparison made: provided the THIN population contains a 
reasonable cross section of the MVC types observed in the general population 
(even if they are not proportionally representative), comparative studies of the 
effects of potential risk factors should produce generalisable results so long as 
the referent group for any comparison is chosen so as to mitigate or eliminate 
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the effect of systematic distortions in the THIN population. For example, the 
differences in the age and sex-specific breakdowns of MVC incidence between 
the THIN population and other sources of data are not problematic provided 
that each age group and sex is well represented in the THIN population and any 
studies of comparative risk use appropriate statistical adjustment or matching 
processes to eliminate any potential distortions due to these factors.  
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3. THE EFFECTS OF MODIFIABLE LIFESTYLE 
FACTORS ON THE RISK OF INVOLVEMENT IN 
MOTOR VEHICLE CRASHES ʹ A CASE-CONTROL 
STUDY 
 45 
 
Abstract 
Background: Previous research suggests that smoking and high body mass 
index (BMI) may increase the risk of MVC (Motor Vehicle Crash). This study 
investigated the individual and combined effects of these factors on the risk of 
involvement in MVCs. 
Methods. Data from THIN were used to conduct a nested case-control 
study. Cases were all individuals aged between 18 and 75 whose records 
indicated involvement in a MVC. 5 controls per case were selected from those 
individuals who had no recorded MVC and were matched to the cases by age, 
sex and general practice. The medical records of all participants were searched 
for recordings of smoking status and BMI. 
Results: After adjustment for potential confounding factors, having a BMI 
greater than 30 kg m-2 was associated with involvement in a MVC (OR=1.15, 
95% CI 1.03-1.29 compared with those having a BMI of between 20 and 25 kg 
m-2). Being an ex-smoker was also associated with involvement in a MVC 
(OR=1.16, 95% CI 1.02-1.32 compared with non-smokers). No significant 
associations were found between current smoking and involvement in MVC.  
Conclusions: Being an ex-smoker and having a BMI greater than 30 kg m-2 
were associated with an increased risk of involvement in a MVC, but these 
results may not be reliable due to poor recording of lifestyle related factors in 
the THIN dataset. 
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Introduction 
Consumption of alcohol is a recognised risk factor for involvement in MVCs, but 
several studies have produced evidence which suggests that other modifiable 
lifestyle factors such as smoking (11-21) and having a high Body Mass Index 
(BMI) (18, 22) may also increase the risk of MVC. A high BMI has also been 
found to be associated with an increase in the severity of injuries due to 
involvement in MVCs (23-27). These factors are interrelated, as smokers are 
more likely to have extreme BMI measurements than non-smokers (28), and 
smoking and a high BMI both increase the risk of serious cardiovascular 
illnesses which may modify the risk of involvement in MVC. In addition, a high 
BMI can lead to the development of obstructive sleep apnoea syndrome, which 
is a recognised risk factor for MVCs (29). This study uses data from THIN to 
investigate the combined effects of smoking and BMI on the risk of involvement 
in MVCs, with adjustment for alcohol consumption and the presence of 
cardiovascular disease and/or obstructive sleep apnoea. 
Initial methods and problems with exposure recording 
Study population 
Data from THIN 255 (November 2004) were used to construct a case-control 
population. Cases were defined as all individuals with a first recorded MVC 
dated on or after the 1st of January 1991, at least one year after the start of the 
computerised medical record and whilst they were aged between 18 and 75 
years. MVCs recorded prior to 1991 were excluded as incidence rates of MVCs 
recorded in THIN increase steeply from nearly nil in the early years of the 
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computerised data to a relatively steady level by the end of 1990. Since 
incidence rates should be mostly unaffected by increases in population size over 
this period, it is likely that this increase is due to changes in quality of data entry 
during this period as practitioners become more adept at maintaining 
electronic records, or progressively move away from paper-based recording. 
The exclusion of events prior to 1991 helps to mitigate any potential bias or 
random error that might be caused by these trends.  
The exclusion of events in the first year of each patieǯ
helps to ensure that MVC (and other) recordings during the study period relate 
to incident events. As discussed earlier, recordings of diagnoses and events with 
the potential to impact patient health over a long period of time are most         ǯ ǡ   
recordings may reflect back entry of paper records or records received from 
previous practitioners, rather than incident events or diagnoses. 
Individuals aged less than 18 were excluded as the minimum age for driver 
licensing in the UK is 17 years. THIN records only indicate the year of birth of 
each patient over the age of 16, necessitating the assignment of an estimated 
month and day of birth for calculations involving age (1st July throughout this 
thesis). In view of the inaccuracy inherent in this approach individuals 
calculated to be aged 17 on the date of MVC were excluded as a substantial 
proportion might in fact have been 16 years of age. Individuals aged over 75 
were excluded as they were felt to be the least likely to be involved in MVCs as 
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drivers (especially given that entitlement to drive requires medical review at 
age 70 in the UK). 
SearchRC ʹ a tool to simplify creation of Read Term lists describing 
exposures and illnesses in THIN 
The Read Clinical Terms list is a hierarchical catalogue of terms used in medical 
records. The majority of data in THIN are stored using a system of codes which 
identify individual Read Terms. In order to identify the presence of a given   ȋ    Ȍ   ǯ ǡ   
necessary to define a complete list of the Read Terms which may be used by 
practitioners to describe that condition. This is a somewhat complicated 
process as the Read Term list is extremely long (~100,000 terms) and contains 
many duplicate codes, synonymous terms, typographical errors and 
abbreviations which might not be immediately obvious to a researcher 
attempting to create a list.  
In view of the size and complexity of the Read Term list, identifying relevant 
codes by manual inspection alone is impractical for studies involving multiple 
conditions or exposures, and highly susceptible to oversights. Entirely 
automated keyword searching is also ineffective as it requires the researcher to 
anticipate every possible variation of terminology or abbreviation prior to 
running the search. The most practical approach is to take advantage of the 
hierarchical structure of the Read Term list, which groups similar terms 
together. Automatic searching can be used to identify likely terms, and the other 
terms in the same category can then be manually inspected to identify 
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variations which might also be relevant. Unfortunately, this is extremely time-
consuming in practice, generally involving loading the Read Term list into a ǲǳ
possible matches (and surrounding terms for each match) for each individual 
keyword. It is also very easy to accidentally omit potentially important codes ǡǲǳ
skipped. 
In order to address this issue I created SearchRC, a new command for STATA 
(STATA Corp. TX, US).  SearchRC performs keyword searches on the Read Term 
list, and includes additional options to permit inspection of related terms. 
SearchRC accepts queries in the following format: 
searchrc keywords, [file() keepcat keeptree csen current] 
SearchRC searches the Read Term list for the specified keyword(s). Either file() 
or current must be specified. File() allows the filename of the Read Term list to 
be specified. Current searches within the current loaded dataset. When using 
multiple keywords, searchRC will find all Read Terms containing one or more of 
the keywords. If a keyword contains a space, it should be enclosed in quotes. 
For example: 
VHDUFKUFRFFXSDWLRQV³0HGLFDO+LVWRU\´FXUUHQW 
Asterisks can be used to search within a description, rather than for the entire 
description. For example:  
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VHDUFKUFHGILOH³&\data\UHDGFRGHVGWD´ 
ǲedǳǢ 
VHDUFKUFTILOH³&\data\UHDGFRGHVGWD´ 
will find all Read terms ǲqǳǢ and; 
VHDUFKUFKHDUWILOH³&\data\UHDGFRGHVGWD´ 
ǲheartǳǤ 
The option current allows searching within previous results (AND searching). 
For example, to find codes for heart disease and Parkinson's disease one might 
use: 
VHDUFKUFKHDUW³SDUNLQVRQ´ILOH³&\data\UHDGFRGHVGWD´ 
searchrc *disease*, current 
The option keepcat additionally returns all other Read Terms in any category 
where a match is found. The option keeptree additionally includes all the Read 
Terms directly above each keyword-matched term in the Read hierarchy. The 
option csen activates case-sensitive keyword searching. 
Using SearchRC to perform keyword searches with the keepcat option activated 
allows the complete Read Term list to be quickly cut down to a much shorter 
list which can be manually inspected to identify the relevant terms for a given 
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diagnosis, event or exposure, or to help identify additional keywords which 
should be included in the search. This considerably simplifies the process of 
compiling Read Term lists, and this software is now in widespread use in the 
Division of Epidemiology and Public Health. 
In the remainder of this thesis, whenever SearchRC was used in the compilation 
of a Read Term list, the keywords used are listed. 
Exposure definitions 
The Read Term dictionary was searched using (a primitive prototype of) 
SearchRC to identify all terms relating to smoking (*smok*, *cigar*, *tobacco*), 
alcohol consumption (*alcoh*, *drink*) and body mass index (*mass*, *body*, 
*weigh*, *bmi*). The completed lists were used to extract all medical and AHD 
table records containing these terms for each patient. In addition, AHD table 
records describing daily cigarette and alcohol consumption and BMI and / or 
separate height and weight measurements were extracted.  
Individuals were classed as smokers, former smokers and non-smokers 
according to the content of the relevant records. Although a substantial number 
of AHD table records (which should indicate levels of smoking) were obtained, 
the overwhelming majority of these contained a string of zeroes (the default 
value) in the ahdval1 field, and were therefore discarded. Records indicating a 
daily cigarette consumption of nil were interpreted as indicating a non-smoker. 
Records indicating that one or more cigarettes were smoked daily were 
interpreted as indicating a smoker. 
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Data from Read Terms indicating a specific level of alcohol consumption were 
combined with direct numerical recordings of alcohol consumption from the 
AHD table to create a categorical representation of daily alcohol consumption 
(based on the categories used by the relevant Read Terms). Records indicating 
only a subjective general level of consumption (light, moderate, heavy etc.) 
were discarded. The following categories were obtained: none; <1 unit / day; 1-
2 units /day; 3-6 units/day; 7-9 units/day; and >9 units/day. 
Data from Read Terms indicating a specific BMI range were combined with 
direct recordings of BMI from the AHD table and estimated values based on 
AHD recordings of height and weight to create a categorical representation of 
BMI. Records indicating only a subjective assessment of body mass 
(underweight, normal, overweight etc.) were discarded. The following 
categories were obtained: <20 kg m-2; 20 to <25 kg m-2; 25 to <30 kg m-2; and  ? ? ?  -2. Since the majority of BMI measurements eventually derived from 
numerical recordings, the use of BMI as a continuous measure was also 
explored. 
Each of these main exposures was defined using the most recent recording 
prior to the date of MVC, but other possibilities were investigated, including 
using the record closest to the date of MVC (whether before or after), the 
earliest recording, or the recording nearest to the date of registration. 
Read Term lists defining cardiac disease (*cardi* *angi* *heart* *ischae*), 
cerebrovascular disease (*cva* *stroke* *tia* *cerebrov*) and obstructive sleep 
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apnoea (*apne*, *apnoe*, *osa*, *obstructive*, *sleep*) were also created. 
Individuals were defined as suffering from each condition of interest if their 
AHD or medical records contained a relevant entry at any time more than 14 
days prior to the date of MVC. 
Frequencies of GP consultation were calculated for each individual to permit 
adjustment for the possibility that smokers, heavy drinkers and those with very 
high or low body mass may visit their GP more often (due to poorer general 
health) and therefore be more likely to report a minor MVC. The frequency of 
consultation was defined as the number of dates on which data were entered in 
each ǯ      prior to the date of MVC, and 
more than one year after the start of the computerised record, divided by the 
duration of this period. Recordings in the therapy table were excluded as repeat 
prescriptions may be issued without a formal consultation.  
Statistical analysis 
The data were analysed using conditional logistic regression models in STATA 
9.1 for Windows XP. Univariate analyses were conducted to estimate the odds 
ratios (OR) of association between smoking and BMI exposure and MVC. 
Likelihood Ratio tests were used to determine whether categorical or 
continuous recordings of BMI provided the best fit. Where complete data for 
individuals were available, two further analyses were used to assess the 
combined effects of the lifestyle factors of interest on the risk of MVC. The first 
investigated the combined effects of smoking and BMI with adjustment for 
alcohol consumption, and the second additionally adjusted for the presence of 
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concurrent illnesses and any differences in consultation frequency 
(transformed to a loglinear scale due to non-normal distribution). 
Problems with this method 
A major problem was encountered when attempting to obtain useable 
measures of smoking status in this population. Individuals in the case 
population were considerably more likely to have a recording of smoking status 
than those in the control population (regardless of the timing of the records 
used). The proportions of smokers in the two populations were similar 
(approximately 25%), but the proportion of recorded non-smokers was 
approximately twice as large among the cases as controls. This pattern of data ǲǳǤ ǡ 
are more motivated to note the presence of a clinically-relevant exposure than 
its absence. Cases had a higher average frequency of consultation than controls, 
so the observed differences in the proportion of non-smokers were presumably 
due to cases having more opportunities to have their non-smoking status 
recorded than controls.  The net result was a substantial ascertainment bias, 
with an over-representation of non-smokers in the case population.  
When attempting to analyse the data in this form, smoking appeared to have a 
strong and highly significant protective effect against involvement in MVC, 
however if all individuals with no recorded smoking status were classed as non-ǡ    ǲǳ        
model, a small but significant positive effect was observed. Neither of these two 
alternative methods was felt to be particularly satisfactory, so the effects of 
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varying the exclusion criteria were investigated in the hope of equalising the 
probability of having a smoking status recorded in the two groups, minimising 
the effects of ascertainment bias. 
Further analyses revealed that by restricting the population to individuals 
registered after the introduction of Vision at each practice, the proportions with 
known smoking status in the case and control groups could be approximately 
equalised. This is presumably a consequence of the fact that smoking status is 
requested as part of the process of adding a new patient to the Vision system, 
leading practitioners to enquire about smoking at the time of registration. 
Unfortunately, restricting the population in this way dramatically reduced the 
number of patients available, and broke the matching process, leading to many 
cases having no matched control due to the controls having been registered 
earlier. At this point it was decided to abandon the analysis and obtain a new 
case-control population properly incorporating this additional criterion. 
Revised methods 
A revised case-control population was obtained using data from the larger THIN 
300 (July 2005) dataset in an attempt to mitigate the loss of statistical power 
due to the exclusion of pre-Vision patients. This version of THIN contains data 
from 300 general practices (including 1.49 million patients registered after the 
introduction of Vision at their practice) around the UK, collected up to July 
2005. Cases were defined as individuals registered after the introduction of 
Vision at their practice whose records indicated involvement in a MVC whilst 
aged between 18 and 75 years. Individuals with a MVC recorded within 1 year 
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of the date of registration were excluded. The control population was randomly 
selected from those individuals with no recorded MVC, matched by age (±3 
years), sex and practice. Each control was required to have a minimum of 1 year 
of computerised medical recording before the date of MVC of their associated 
case, to have been registered after the introduction of Vision at their practice, 
and to be living in a different household to the case. Where possible, 5 controls 
were matched to each case. 
Data extraction 
The most recent recordings of smoking status, BMI and alcohol consumption 
recorded more than 14 days prior to the date of MVC were extracted for each 
individual in the study population. Individuals were defined as suffering from 
cardiac disease, cerebrovascular disease or obstructive sleep apnoea at the time 
of MVC if their record contained any record contained a diagnosis of that 
condition in the same time period. 
The treatment of BMI and smoking records in this analysis was exactly as 
before, but unfortunately the alcohol consumption data were far poorer in this 
population than previously (presumably due to the reduced duration of follow-
up). Very few individuals (~30%) had a recording of alcohol consumption 
indicating a specific range or amount, so individuals were classed only as 
consumers or non-consumers of alcohol. 
Frequencies of GP consultation were calculated for each individual to permit 
adjustment for the possibility that individuals visiting their GP regularly due to 
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ill health caused by smoking, alcohol consumption or high or low body mass 
may be more likely to report a MVC. The frequency of consultation was defined ǯ 
and AHD table records more than 14 days before the date of MVC, and more 
than one year after the start of the computerised record, divided by the 
duration of this period. 
 
Analysis 
The data were analysed using conditional logistic regression models in STATA 
9.1 for Windows XP.  As before, univariate analyses were conducted to estimate 
the odds ratios (OR) of association between smoking and BMI exposure and 
MVC. Likelihood Ratio tests were used to determine whether categorical or 
continuous recordings of BMI provided the best fit. Where complete data for 
individuals were available, two further analyses were used to assess the 
combined effects of the lifestyle factors of interest on the risk of MVC. The first 
investigated the combined effects of smoking and BMI with adjustment for 
alcohol consumption, and the second additionally adjusted for the presence of 
concurrent illnesses and any differences in consultation frequency 
(transformed to a loglinear scale due to non-normal distribution). 
A power calculation performed using Egret SIZ for MS-DOS (Cytel Software, 
Cambridge, MA) suggested that a population of 3,653 case-control sets would 
have 90% power to detect an Odds Ratio of 1.15 at the 5% significance level, 
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assuming a population of 57% males and 43% females, with 24% of women and 
28% of men being current smokers, and a 3:1 control:case ratio. 
Results  
The basic characteristics of the study population are shown in Table 13. Cases 
and controls were well matched for socio-economic status. Smoking status at 
registration was available for 60% of the study population and data on the 
number of cigarettes smoked per day were available for 66% of smokers. Data 
on BMI were available for 79% of the population and data on alcohol 
consumption were available for 82%.  
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Table 13: Socio-demographic characteristics and lifestyle exposures of MVC cases 
and controls in THIN 300 (July 2005) 
       
        
  
Characteristic 
Cases   Controls   
 Male Female  Male Female  
  (n=3383) (n=3760)   (n=16364) (n=18386)   
 Age at time of crash       
  Years, median (interquartile range) 34 (27 ± 41) 32 (25 ± 40)  34 (28 ± 42) 32 (26-40)  
        
 Quintile of Townsend deprivation index       
 
 1st; least deprived, n (%) 
 2nd, n (%) 
 3rd, n (%) 
 4th, n (%) 
 5th; most deprived, n (%) 
 Not available, n(%) 
716 (21.2%) 
586 (17.3%) 
595 (19.6%) 
628 (18.6%) 
508 (15.0%) 
350 (10.4%) 
902 (24.0%) 
684 (18.2%) 
693 (18.4%) 
611 (16.3%) 
486 (12.9%) 
384 (10.2%)  
3508 (21.4%) 
2783 (17.0%) 
3136 (19.2%) 
2839 (17.4%) 
2462 (15.0%) 
1636 (10.0%) 
4253 (23.1%) 
3394 (18.5%) 
3403 (18.5%) 
3147 (17.1%) 
2401 (13.1%) 
1788 (9.7%)  
        
 Body mass index (BMI)*       
  BMI<20 kg m-2, n (%) 199 (5.9) 392 (10.4)  931 (5.7) 1983 (10.8)  
  20BMI<25 kg m-2, n (%) 1025 (30.3) 1501 (39.9)  5161 (31.5) 7245 (39.4)  
  %0,NJP-2, n (%) 943 (27.9) 784 (20.9)  4504 (27.5) 3711 (20.2)  
  BMI0 kg m-2, n (%) 455 (13.5) 556 (14.8)  1602 (9.8) 2281 (12.4)  
  not recorded, n (%) 761 (22.5) 527 (14.0)  4166 (25.5) 3166 (17.2)  
        
 Smoking status*       
  non-smoker, n (%) 605 (17.9) 974 (25.9)  3041 (18.6) 4926 (26.8)  
  ex-smoker, n (%) 249 (7.4) 298 (7.9)  966 (5.9) 1267 (6.9)  
  smoker, n (%) 1169 (34.6) 1153 (30.7)  5289 (32.3) 5300 (28.8)  
  not recorded, n (%) 1360 (40.2) 1335 (35.5)  7068 (43.2) 6893 (37.5)  
        
 Alcohol consumption*        
  non-consumers of alcohol, n (%) 222 (6.6) 316 (8.4)  980 (6.0) 1682 (9.2)  
  consumers of alcohol, n (%) 2509 (74.2) 2958 (78.7)  11859 (72.5) 13907 (75.6)  
  not recorded, n (%) 652 (19.3) 486 (12.9)  3525 (21.5) 2797 (15.2)  
        
 Consultation rate

       
  uniquely dated GP recordings per year, median (IQR) 2.9 (0.8-6.3) 7.0 (3.5-12.4)  1.5 (0.0-4.6) 4.9 (1.6-10.0)  
        
 Medical conditions*       
  cardiac disease, n (%) 138 (4.1) 92 (2.5)  496 (3.0) 379 (2.1)  
  cerebrovascular disease, n (%) 17 (0.5) 13 (0.4)  78 (0.5) 68 (0.4)  
  obstructive sleep apnoea, n (%) 9 (0.3) 0 (0)  27 (0.2) 6 (0.0)  
           
        
* recorded up to 14 days prior to MVC        
 based on period between 365 days after registration and 14 days before MVC     
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The unadjusted analysis showed significantly increased risks of involvement in 
a MVC among individuals with a BMI of 30 kg m-2 or greater (OR=1.27 | 95% 
Confidence Interval CI: 1.17-1.38) relative to those with BMI of 20 to 25 kg m-2  
Current smokers (OR=1.08 | 95% CI: 1.00-1.17)and ex-smokers (OR=1.24 | 95% 
CI: 1.10-1.39) were also at an increased risk of involvement in MVC  relative to 
non-smokers (Table 14), as were individuals with a diagnosis of cardiac disease 
(OR=1.33 | 95% CI 1.14-1.56).  
Table 14: Univariate and multivariate analysis of lifestyle-related risk factors for 
MVC in THIN 300 (July 2005) 
 
In the multivariate analysis, after mutual adjustment for smoking status, alcohol 
consumption and BMI, having a BMI of 30 kg m-2 or greater (OR=1.25 | 95% CI: 
1.11-1.39) and being an ex-smoker (OR=1.23 | 95% CI: 1.08-1.39) remained 
statistically significant, but there was no association between involvement in a 
MVC and current smoking (OR=1.05 | 95% CI: 0.96-1.15). Following adjustment 
for the effects of concurrent illnesses and for differences in frequency of 
  
Risk Factor 
Unadjusted Model  Adjusted Model A Adjusted model B   
  
OR (95% confidence 
interval) p 
OR (95% confidence 
interval) p 
OR (95% confidence 
interval) p   
 smoking status        
 non-smoker 1.00 - 1.00 - 1.00 -  
 ex-smoker 1.24 (1.10-1.39) <0.01 1.23 (1.08-1.39) <0.01 1.16 (1.02-1.32) 0.02  
 current smoker 1.08 (1.00-1.17) 0.05 1.05 (0.96-1.15) 0.27 1.02 (0.93-1.12) 0.67  
  n=4,308  n=3,762  n=3,762   
         
 
body mass index (by 
category)        
  BMI<20 kg m-2 0.98 (0.88-1.08) 0.65 0.96 (0.84-1.10) 0.55 0.95 (0.83-1.09) 0.50  
 20BMI<25 kg m-2 1.00 - 1.00 - 1.00 -  
  %0,NJP-2 1.04 (0.97-1.11) 0.30 0.98 (0.89-1.07) 0.61 0.96 (0.87-1.05) 0.34  
  BMI0 kg m-2 1.27 (1.17-1.38) <0.01  1.25 (1.11-1.39) <0.01 1.15 (1.03-1.29) 0.01  
  n=5,815  n=3,762  n=3,762   
                  
 n=number of cases with complete data with at least one matched control with complete data     
 Model A : Adjusted for smoking status + BMI + alcohol consumption       
 Model B : Additionally adjusted for concurrent illnesses and frequency of consultation    
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consultation, the associations between having a BMI>30 (OR=1.15 | 95% CI: 
1.03-1.29) and being an ex-smoker (OR=1.16 | 95% CI: 1.02-1.32), and 
involvement in a MVC persisted. 
Discussion  
This is the first population-based study in the UK investigating the associations 
between smoking, BMI and alcohol consumption and involvement in a MVC. The 
results suggest that, following adjustment for potential confounding factors, 
having a BMI of greater than 30 kg m-2 is associated with a 15% increased risk 
of involvement in a MVC compared with those with a BMI between 20 and 25 kg 
m-2, and being an ex-smoker is associated with a 16% increased risk of 
involvement in a MVC compared with a non-smoker. Current smoking was not 
found to be associated with an increased risk of involvement in a MVC. 
The strengths of this analysis are the large size of the study population 
(covering 1.49 million individuals), the prospective nature of the data collection 
and the comprehensive coverage of significant medical events due to the 
universal coverage of health care in the UK and the gatekeeper role of primary 
care providers in implementing this system. The data used in this study were 
collected between 1994 and 2005 and are therefore relevant to the current 
driving conditions in the UK.  
The analysis has two important limitations. The outcome indicator is specific 
for MVC, but the exact nature of each crash is unclear and it is not possible to 
determine whether those involved were driving, passengers or pedestrians. The 
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presence of non-drivers in the population would tend to introduce random 
error and reduce the magnitude of the observed associations. A more serious 
problem is the poor recording of lifestyle-related exposures in THIN. Data on 
smoking status, alcohol consumption and BMI were unavailable for 40%, 18%, 
and 21% of individuals respectively. Complete data on all exposures of interest 
were available for fewer than 50% of cases and controls, so there is much 
potential for distortion of the results due to ascertainment bias. 
A number of previous epidemiological studies have reported associations 
between involvement in a MVC and smoking, predominantly in drivers, 
suggesting that smoking may impair the ability to drive safely, but none of these 
studies adjusted for alcohol use, BMI, and concurrent disease simultaneously. 
Case-control studies have found that smokers have an increased risk of 
involvement in a MVC (12, 13) and an increased risk of death due to 
involvement in a MVC compared with non-smokers (30), that those who 
routinely smoke whilst driving have an increased risk of involvement in a MVC 
compared with those who do not (18), and that smoking is more common 
amongst those who have had crashes, traffic code violations and licence 
suspensions than amongst those reporting no crashes or violations (11). Cross-
sectional studies have also reported associations between smoking and 
increased risk of involvement in a MVC (15, 19) and traffic violations (15). Most 
recently, a cross-sectional study of 1,214 drivers attending health centres in the 
city of Zaragoza, Spain, found that the number of recorded MVCs was 
significantly higher amongst smokers when compared with non-smokers 
(OR=2.2), regardless of whether smokers smoked whilst driving or not (14).  
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Cohort studies have also produced similar findings. Analysis of surveillance 
data from a cohort of 7,863 petrochemical workers across the United States 
found that male smokers were 75% more likely to be involved in MVCs 
resulting in over 5 days absence from work between 1985 and 1987, but found 
no excess risk among ex-smokers (20). The risk of death due to MVC amongst 
smokers in a cohort of 82,461 participants in the United States National Health 
Interview Survey followed up between 1990 and 1995 was found to be 2.1 
times that of non-smokers following adjustment for age, race, gender, level of 
education, marital status and level of alcohol consumption, but no adjustments 
were made for the presence of pre-existing medical conditions (17). Similarly, 
the risk of death due to MVC among smokers in a cohort of 64,319 Taiwanese 
males between 1982 and 2001 was found to be 1.9 times that of non-smokers 
after adjustment for age and alcohol use (21). 
The observations in THIN, which suggest that being an ex-smoker but not a 
current smoker is associated with involvement in MVC, is at odds with those of 
earlier studies, which consistently demonstrate an association between being a 
smoker and involvement in MVC. In addition, the results obtained from THIN 
are implausible Ȃ it is difficult to conceive of a reason why ex-smokers should be 
more at risk of involvement in MVCs than current smokers. 
The THIN population is very large, and should provide sufficient power to 
detect an association of the size suggested by previous findings,  By far the most 
likely explanation for the absence of an association with current smoking is the 
poor quality of exposure recording in the THIN data. Surveys in primary care 
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also suggest that recordings of smoking status in GP records are often 
inaccurate (31). It is also likely that some of the discrepancy is a result of 
selecting cases solely as a consequence of having been involved in a MVC, while 
most of the existing literature has specifically focussed on drivers. This 
uncertainty over the precise nature of each MVC Ȃ in particular as to whether 
the case was driving or not - would tend to reduce the magnitude of any 
observed association towards unity if the effect was only present in drivers who 
smoke.  
Explaining the presence of an association among ex-smokers in the absence of 
an association among smokers is more difficult. It is possible that a significant 
proportion of ex-smokers are in fact misclassified current smokers. 
Alternatively, the association between being an ex-smoker and involvement in 
MVAs may be a true one. Ex-smokers are, by definition, older on average than 
current smokers. Older individuals are more likely to have a record of smoking 
status. This may have made it possible to detect an association in this group 
whilst the poor ascertainment among younger individuals may have obscured 
any association among current smokers. Ex-smokers may have stopped 
smoking due to deteriorating health that may not have led to overt disease, but 
that may have impaired driving ability such as impaired vision (32), subclinical 
cardiac disease or respiratory problems (33). In addition, ex-smokers are likely 
to share behavioural characteristics with current smokers which may lead to an 
increased risk of MVC. Alternatively, this may simply be a chance (incorrect) 
finding. 
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The results of this study are consistent with previous findings that a high BMI is 
associated with an increased risk of MVC. A high BMI has also been linked with 
an increased risk of Obstructive Sleep Apnoea (OSA), which is an established 
risk factor for MVC (29), and although the results are adjusted for the presence 
of a diagnosis of OSA, it is likely that there is a significant prevalence of 
undiagnosed OSA in the THIN population (34). The association between 
increased BMI and involvement in a MVC may be a consequence of the presence 
of other subclinical health problems such as cardiovascular disease amongst 
those with high BMI (35). Alternatively, the relation between BMI and risk of 
involvement in MVC may be confounded by greater annual mileage amongst 
those with high BMI due to an inability to walk long distances, or to a tendency 
to gain weight amongst those who routinely make short journeys by car. 
Nonetheless, if a raised BMI is a risk factor for involvement in a MVC, this raises 
the possibility that regular medical surveillance for common treatable diseases 
in obese adults who drive may be one approach that has potential to reduce risk 
of involvement in MVCs. 
Conclusions 
The results of this study suggest that previously having smoked and having a 
high BMI may both be associated with an increased risk of involvement in 
MVCs. There was no evidence of an increased risk among current smokers. 
These findings should be interpreted cautiously as the recording of lifestyle 
related exposures in the study population is poor, and the statistical analysis is 
based on only a small portion of the overall population. The results with regard 
to smoking contradict several previous findings from studies with more robust 
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data collection, suggesting that THIN is not ideally suited to studying the effects 
of such factors in a population with a young age structure. Further analyses 
should concentrate on those areas where THIN data can be considered more 
reliable. 
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4. META-ANALYSIS OF OBSERVATIONAL STUDIES 
OF THE ASSOCIATION BETWEEN SMOKING AND 
INVOLVEMENT IN MVCS 
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Introduction 
In recognition of the problems with using THIN data to produce an adequately 
adjusted analysis of the risk of MVC associated with smoking, and in order to 
provide a more balanced perspective on this issue, a meta-analysis of existing 
epidemiological studies in this area was carried out. 
Methods 
Identification of relevant studies 
A systematic search of the published literature was performed to identify 
studies reporting risks of involvement in, or death or injury due to MVCs in 
smokers compared with non-smokers. EMBASE (1980 to week 31 2007), 
Medline ǲǳȋ ? ? ? ? ? ? ? ? ? ?Ȍ, CINAHL (1982 to week 31 
2007), AMED (1985 to week 31 2007) and the British Nursing Index (1985 to 
week 31 2007) were searched using the following keyword query: 
(smok$ OR cigar$ OR tobacc$ OR pipe OR nicotin$) AND (motor OR 
vehic$ OR road OR crash$ or automobi$ OR collision OR driv$) 
In addition, conference abstracts from the Society for Research on Nicotine and 
tobacco in the last 3 years were searched for relevant reports. Attempts were 
made to contact the lead authors of all potentially relevant papers published 
since 1990 in order to identify any additional relevant research. 
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Data extraction 
Three researchers independently read and extracted data from each identified 
study. In the small number of instances where studies subdivided smoking 
status into more than two levels, data were extracted describing the 
comparative risk of MVC among smokers vs. non-smokers. Each study was 
assessed for quality using the Newcastle Ottawa Scale (NOS) (36). All 
discrepancies were resolved by consensus. 
Analysis 
Data were analysed using the Cochrane Collaboration Reviews Manager v5 for 
Windows Vista. Cohort studies were analysed separately from case-control and 
cross-sectional studies. Fixed effects models were used to calculate pooled 
estimates and 95% confidence intervals in view of the small number of studies 
available. Funnel plots were created to assess the potential for publication bias.  
Results  
After initial inspection of the abstracts and titles of the 17,463 papers identified 
by the electronic search, 27 full papers were obtained for review. Of these, 8 
were eventually included in the meta-analysis. Figure 13 outlines the search 
process. The papers included in the analysis are listed in Table 15. Data from 
the analysis in THIN were excluded in view of the problems with exposure 
recording outlined previously.  
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 Full Texts retrieved 
n=27 
Included papers 
n=8 
Not relevant 
n=14 
Relevant observational studies  
n=13 
 
 
Data in unsuitable format 
n=5 
Figure 13: Search process for meta-analysis 
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Table 15: Studies included in meta-analysis 
Lead Author Year Design n Exposure Definition 
Outcome 
definition 
Confirmed 
Drivers? 
Quality 
Score* 
        
Liddell (18) 1982 Case-control 694 Any smoking whilst driving y/n Crash Yes 6 
Grout (16) 1983 Case-control 127 Any Smoking y/n Injury Yes 6 
DiFranza (15) 1986 Cross-sectional 3,714 Cigarette smoking y/n Crash Yes 4 
Tsai (20) 1990 Cross-sectional 7,863 Any Smoking y/n Injury No 5 
Leistikow (17) 2000 Cohort 82,461 Cigarette smoking y/n Death No 9 
Avi (12) 2001 Case-control 29,212 Cigarette smoking y/n Injury Yes 7 
Bunuel-Granados (14) 2003 Cross-sectional 1,214 Any Smoking y/n Crash Yes 6 
Wen (21) 2005 Cohort 64,319 Cigarette smoking y/n Death No 8 
                
        * Newcastle-Ottawa scale 
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Forest plots illustrating the individual study estimates and pooled results are 
given in Figure 14 and Figure 15. The pooled results from the two cohort 
studies suggest that the relative risk of a fatal MVC among smokers is 1.87 (95% 
CI 1.46 to 2.41). There was no evidence of heterogeneity between these two 
studies. The pooled results from the case-control and cross-sectional studies 
suggest that the odds ratio for involvement in MVC among smokers (compared 
to non-smokers is 1.68 (1.49 to 1.98). There was clear evidence of 
heterogeneity between these studies.  
Figure 14: Forest plot of relative risk of involvement in a fatal MVC for smokers 
relative to non-smokers 
 
Figure 15: Forest plot of odds ratio of association between current smoking and 
involvement in MVC 
 
Study or Subgroup
Leistikow
Wen
Total (95% CI)
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 4.89 (P < 0.00001)
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Avi
Bunuel
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Heterogeneity: Chi² = 4.53, df = 4 (P = 0.34); I² = 12%
Test for overall effect: Z = 6.21 (P < 0.00001)
log[Odds Ratio]
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0.19
0.2
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1.79 [1.23, 2.60]
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Funnel plots for the cohort and case-control/cross-sectional studies are given in 
Figure 16 and Figure 17 respectively. There was no evidence of publication bias 
in either group. 
Figure 16: Funnel plot for cohort studies of association between smoking and 
death due to MVC 
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Figure 17: Funnel plot for case-control and cross-sectional studies of association 
between smoking and involvement in MVC 
 
Discussion 
The pooled estimates from the meta-analysis suggest that smoking is associated 
with a 70 to 90 percent increase in the risk of MVC. The two cohort studies were 
methodologically very similar and produced similar individual estimates of the 
magnitude of association, suggesting that the pooled analysis is appropriate. 
The observed effects in the case-control and cross-sectional studies were less 
consistent and there was evidence of heterogeneity between the studies. This is 
unsurprising given the diverse range of data sources and outcomes (Table 15 
and discussion in previous chapter). 
The Newcastle-Ottawa scores suggest that the overall methodological quality of 
the included studies was fair, although only one study achieved the highest 
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possible score (9 marks), and it should be noted that there is currently no 
widely-ǲ-ǳǲ-ǳ
studies. The Newcastle Ottawa scale assesses study quality in three main areas Ȃ the appropriateness of the case selection method (up to 4 marks), the 
comparability of the control or unexposed group (up to 2 marks) and the 
assessment of exposure status and major confounders (up to 3 marks). Other 
quality assessment schema exist, but the Newcastle Ottawa score was chosen         ǯ   
nonrandomised studies. Newcastle Ottawa scores can be used to assess the 
impact of study design quality on the observed size of effect (by dividing studies 
into ranges of NOS score), but this was not considered worthwhile in this case 
in view of the small number of qualifying studies. 
Overall, in spite of the small number of useable studies, it seems reasonable to 
conclude that smoking is indeed associated with an increased risk of MVC. 
Unfortunately, it is not possible to derive any firm conclusions about the 
mechanisms underlying this association from the current literature. Two 
studies have compared the risk of MVC between individuals who habitually 
smoke whilst driving and non-smokers (14, 18), but none has attempted to 
compare the risks between smokers who habitually smoke whilst driving and 
other smokers who do not. It is not, therefore, possible to determine whether 
the increase in risk is due to smoking in general or smoking whilst driving in 
particular. 
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 There are a number of possible mechanisms which may explain the observed 
association. A smoky atmosphere within a vehicle may reduce visibility, as may 
residues deposited on the windscreen (13). The act of smoking may distract ǯ    Ǣ     
drivers suggests that drivers are distracted when lighting cigarettes, although 
there was no evidence of an overall deterioration in performance (37). 
Similarly, dropping a hot cigarette within a vehicle might lead to a loss of 
control. Alternatively, the short term effects of smoking may impair co-
ordination or response times Ȃ high blood carbon monoxide levels have been 
shown to impair performance in driving simulation studies, and changes in 
blood nicotine levels have been demonstrated to affect (but not necessarily Ȍǯ (38, 39).  
A particular complication of this association is the behaviour of smokers. 
Smoking is associated with a range of risk-taking behaviours, including drunk-
driving and other forms of dangerous driving (40, 41), and failure to wear seat 
belts (16, 42, 43). These behavioural characteristics make smokers inherently 
more likely to be involved in a MVC, and it is unlikely that any study which did 
not involve direct observation of the circumstances surrounding a crash would 
be able to disentangle this effect from the more mechanical and physiological 
processes which may also contribute to an increased risk. 
Conclusions 
The available body of research provides clear evidence that the risk of MVCs is 
higher among smokers than among non-smokers, but it is not possible to 
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determine either whether this effect is limited to those who smoke whilst 
driving, or whether the association is confounded by the behavioural 
characteristics of smokers.    
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5. THE EFFECTS OF PRESCRIBED MEDICATIONS ON 
THE RISK OF MOTOR VEHICLE CRASHES ʹ A SELF-
CONTROLLED CASE-SERIES STUDY 
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Abstract 
Background. Previous studies have reported inconsistent associations between 
use of certain medications and involvement in a motor vehicle crash (MVC).  
Study design and methods. This study investigated the impact of taking 
benzodiazepines, non-benzodiazepine hypnotics, beta-blockers, selective 
serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, opioids and 
antihistamines on the risk of MVC, using data from THIN. The self-controlled 
case series method was used to compare the incidence of a MVC when exposed 
to each medication with the incidence when unexposed. 
Results. 49,821 individuals aged 18-74 had documented involvement in a 
MVC. The first four weeks of treatment with a combined acetaminophen and 
opioid preparation was associated with an increased risk of MVC (Incidence 
Rate Ratio=2.06, 99% Confidence Interval 1.84, 2.32) as was the use of an 
opioid alone (IRR=1.70, 99% CI 1.39, 2.08). The use of SSRIs (IRR=1.16, 99% CI 
1.06, 1.28), non-benzodiazepine hypnotics (IRR=1.37, 99% CI 1.05, 1.79) and 
antihistamines (IRR=1.21, 99% CI, 1.04, 1.41) for more than 4 weeks was 
associated with MVC but shorter term use was not. The use of beta-blockers and 
tricyclic antidepressants was not associated with an increased risk of MVC.  
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Conclusions. The use of benzodiazepines and preparations containing opioid 
analgesics is associated with an increased risk of involvement in MVCs. Longer 
term use of SSRIs, antihistamines and non-benzodiazepine hypnotics may also 
increase the risk of MVC. There was no evidence of any increased risk among 
users of beta-blockers or tricyclic antidepressants. 
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Introduction 
Studies describing the effects of prescribed medications suggest that driving 
performance may be impaired by the use of benzodiazepines (44), tricyclic 
antidepressants (45), opioids (46), beta-blockers (46), antihistamines (47) and 
non benzodiazepine sedatives such as zopiclone (48). Users of these 
medications may be at increased risk of MVC, but controlled epidemiological 
studies assessing the actual effect of taking medication on the risk of MVC are 
scarce. Available data suggest that the risk of MVC involvement is increased by 
the use of sedatives such as zopiclone (49) and the benzodiazepines (49-55) but 
studies of the effects of taking tricyclic antidepressants (49, 51, 55) and opioids 
(49, 55) have produced inconsistent results. 
This study uses data from THIN to assess the risk of MVC among individuals 
taking a selection of medications which may affect co-ordination or alertness. 
Methods I ʹ Case crossover analysis and problems with this approach 
The largest and most often cited study of the effects of taking prescribed 
medications on the risk of MVCs to date was published in 1998 by Barbone et al 
(49). This study linked data from police accident records with information from 
the prescription pricing authority (PPI) listing all the medications used by the 
drivers in the year prior to the date of MVC. To avoid the difficulty and expense 
of recruiting a suitable control population, the study used a case-crossover 
method, whereby the odds of having received a prescription for a medication of 
interest in the month immediately prior to the date of MVC was compared with             ǯ
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record. In effect, a case-crossover study is analogous to a case control study, 
where case individuals and control individuals are replaced with at-risk (ǲǳȌ
and not at- ȋǲǳȌ         
individual. The data are then analysed using logistic regression conditioned on 
the individual. The initial aim of the work described in this chapter was to 
update the earlier study, using the same methods to investigate the association 
between medication use and involvement in MVCs in the larger population and 
longer follow-up available in THIN. 
Study population and selection of time periods for comparison 
The study population comprised all individuals with a first recorded MVC dated 
at least 1 year after the start of their computerised THIN record who were aged 
18-74 at the time. Individuals whose MVC records indicated that they were not 
driving at the time were excluded. In line with the previous study, the at-risk 
period was defined as the four-week period immediately prior to (and 
excluding) the date of MVC. The not at-risk period was defined as the four-week 
period immediately prior to the at-risk period. 
A key assumption of the case-crossover method is that the risk of exposure in 
the not-at-risk period is should appropriately reflect the backround risk of 
exposure (56). That is, that the results should be independent of the choice of 
not at-risk period. To test this assumption in the THIN population, three 
additional not at-risk periods were defined (each 4 weeks in length, 
successively extending back to 16 weeks prior to the beginning of the at-risk 
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period), so that the degree of variation in the results with differing choices of 
control period could be assessed.   
Exposure ascertainment 
The therapy table records for each individual in the study population were 
searched for recordings indicating the prescription of any benzodiazepine, non-
benzodiazepine hypnotic, beta-blocker, opioid, compound analgesic 
(acetaminophen + opioid), tricyclic antidepressant, selective serotonin reuptake 
inhibitor (SSRI) or anti-histamine preparation dated prior to the date of MVC. 
Individuals were considered exposed or unexposed to each class of medication 
whilst at-risk or not at-risk of MVC according to the presence or absence of a 
suitable prescription record within the relevant time periods. 
Analysis 
The data were analysed using conditional regression models in StataSE v9.1 
(Stata Corp. TX, USA) for Windows XP. The use of case-only methods has the 
advantage of implicitly controlling for the effects of fixed (per individual) 
confounding. In effect, the effects of any potential confounding factors which 
vary between individuals but which do not vary substantially for any single 
individual during the period of study are removed.  For this reason, and to     ǲǳ ǡ    
made. 
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Results I ʹ failure to meet necessary assumptions 
When the results were obtained, it quickly became apparent that the 
assumption of equivalency of control periods was not met in the THIN data. The 
results for all categories of medication were unstable, leading to substantially 
differing estimates of effect size and of statistical significance. Figure 18 shows 
the differing results obtained with successive not-at risk periods for opioid 
medications. Depending on the choice of not at-risk period, the estimated Odds 
Ratio varies by over 20%, and the result may or may not be statistically 
significant. Similar instabilities were observed for each of the categories of 
medication under investigation, making use of the case-crossover method 
inappropriate in these data. 
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Figure 18: Odds ratio of association between involvement in MVC and receipt of a 
prescription for an opioid using 4 successive 4-week control periods prior to the 
at-risk period 
 
It is interesting to note that while the THIN data fail to comply with the 
necessary assumption, experimentation with different control periods in the 
earlier study did not reveal similar instability. One possible explanation is the 
likely presence of non-drivers in the THIN population, which may have reduced 
the magnitude of the observed associations sufficiently that relatively small 
variations in probability of exposure with different not at-risk periods may have 
constituted a larger proportion of the overall odds ratio, making the instabilities 
more obvious. Alternatively, the reliance on issued prescriptions as a measure 
of exposure in the THIN data, rather than collected prescriptions in the PPI data, 
may have magnified any variations if a substantial proportion of prescriptions 
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are not collected. Whatever the explanation, the failure of this technique to 
produce stable results in the THIN data prevents robust conclusions from being 
drawn from the results. 
Methods II ʹ The self-controlled case-series approach 
In view of the failure of the case-crossover method to produce stable results, the 
decision was taken to repeat the analysis using the more complicated self-
controlled case-series approach. The case series method was originally 
developed to permit study of adverse reactions to childhood vaccinations (56, 
57) but has been applied successfully in a variety of other situations, including 
several pharmacoepidemiological studies using THIN data (58-61). The case-
series method is similar in principle to the case-crossover method; if the case-
crossover method is analogous to a case-control study, the case-series method 
is analogous to a cohort study. The case-series method divides individual 
patient follow-up time into exposed and unexposed periods, between which the 
incidence rates of the outcome of interest are compared. Like the case-
crossover method, the case-series approach implicitly controls for the effects of 
fixed (per individual) confounding factors, but does not require a constant 
probability of exposure outside the time period immediately prior to the 
outcome, so the variations observed in the THIN data do not prevent use of this 
method. The case-series method additionally permits exploration of changes in 
risk with duration of exposure, and has been shown to approach cohort 
methodologies in terms of statistical power (56). 
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Study population 
As before, the study population comprised all individuals with a first recorded 
MVC dated at least 1 year after the start of their computerised THIN record who 
were aged 18-74 at the time. Individuals whose MVC records indicated that they 
were not driving at the time were excluded. 
Exposure ascertainment, and a note about the exposures investigated 
The therapy table records for each individual in the study population were 
searched for prescriptions for any benzodiazepine, non-benzodiazepine 
hypnotic, beta-blocker, opioid, compound analgesic (paracetamol + opioid), 
tricyclic antidepressant, selective serotonin reuptake inhibitor (SSRI) anti-
histamine or protein pump inhibitor (PPI) preparation. Although the therapy 
table includes variables which either directly indicate, or can be used to 
calculate the duration of a given prescription, in practice, these are rarely used 
in data recorded prior to the introduction of Vision (and even then, a substantial 
proportion are missing). To avoid restricting the population and losing 
statistical power, the therapy table records for each class of medication, and 
also for each medication, were grouped into estimated courses of treatment 
based on the interval between prescription dates. The modal interval between 
prescription dates within each category of medication was found to be 4 weeks, 
with further discernable peaks at 8, 12 and 16 weeks and a steady baseline 
thereafter, in line with normal prescribing practice in the United Kingdom. The 
conservative assumption was therefore made that prescriptions were part of an 
ongoing course of treatment if they were dated within 16 weeks of a prior 
prescription for a drug in the same class. Prescriptions issued prior to the start 
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of follow-up were examined in order to determine the correct exposure status 
of each individual at the start of follow-up, but no person-time from this period 
was included in the analysis. Prescription records in THIN do not exhibit the 
patterns of recording associated with back entry of historical data which are 
observed in the diagnostic data. 
It is important at this point to explain the reasoning behind the final selection of 
medications investigated in this study. The original intention was to study the 
effects of the benzodiazepines, non-benzodiazepine hypnotics, SSRIs, opioid and 
combined paracetamol and opioid analgesics, and the tricyclic antidepressants 
as these medications are only available on prescription in the UK and are 
normally prescribed for a limited period of time. The beta-blockers were 
included at the insistence of the ethics committee which approved the study, 
however the results obtained for this class of medication should be interpreted 
cautiously, as a key assumption of the case series method is that exposure is 
only temporary, and should be of short duration compared with the overall 
period of follow-up. Beta-     ǲ-of-ǳ
medications for the treatment of chronic cardiovascular conditions and cannot 
reasonably be expected to meet this requirement. The anti-histamines were 
included at the request of a Lancet peer-review panel. Again, the results for 
these medications should be interpreted cautiously as many are available over 
the counter, and can often be obtained more cheaply in this way for individuals 
who are not exempt from UK prescription charges. Given the age structure of 
the population of individuals involved in MVCs, it is unlikely that a substantial 
proportion of the population is exempt from charging, so the exposure 
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ascertainment is likely to be inaccurate for this group of medications. The PPIs 
were also included at the request of the review panel in order to provide a ǲ ǳ ȋ         
performance) to determine whether spurious positive associations might arise 
due to the choice of exposure periods (see next section).  
Statistical analysis 
For each class of medication, and for each individual compound within each 
class, a separate dataset was created for analytical purposes, dividing the 
follow-up time for each exposed case into different periods according to 
exposure status. 6 different categories were defined (Figure 19): 
Figure 19: Exposure-time categories for case-series analysis 
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1. Time when unexposed to the medication of interest (baseline). 
2. A four week period up to and including the date of the start of each course of 
treatment. 
3. The four weeks immediately following the start of a course of treatment 
(starting the day after the date of first prescription). 
4. The remainder of that course of treatment, ending 4 weeks after the last 
prescription. 
5. The first 12 weeks after the end of each course of treatment 
6. The second 12 weeks after the end of each course of treatment 
The first category represents baseline time, to which other exposure-time 
categories are compared. Since many of the medications of interest could be 
used to treat anxiety or pain caused by a MVC it is necessary to include the 
second category, a pre-exposure time period which removes any MVCs which 
might have led to the issue of a prescription from the calculation of the baseline 
incidence rate, thus preventing any spurious inflation of this quantity. The 
number of prescriptions for any medication of interest issued on each day 
subsequent to the date of accident was inspected graphically and found to 
decline, from a peak on the day of accident, to a steady baseline within 4 weeks, 
hence this was the duration chosen for this category. 
The time during which individuals were exposed to each medication of interest 
was divided into two categories to investigate whether any changes in the risk 
of MVC are short-lived (while patients adjust to their medication), develop over 
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time (only become apparent with extended use) or are constant. The fifth and 
sixth periods were included to investigate withdrawal effects; most individuals 
would have discontinued their use of the medication by the start of the fifth 
period, whilst those on 8, 12 or 16-week prescriptions would have discontinued 
use by the start of the sixth period. In cases where a new course of treatment 
began during either of these last two periods, the exposure statuses associated 
with the new course took preference. 
Data were analysed using Stata 9SE for Windows XP. Fixed-effects Poisson 
regression models were used to calculate incidence rate ratios (IRRs) 
comparing the incidence rates of MVC in each exposure category with the 
incidence rate during the baseline period. Within each drug class, the effects of 
taking individual medications on the risk of MVC were assessed where a 
minimum of 450 exposed cases were available.  
Whilst the case-series method controls for confounding by factors which are 
constant within each individual, it does not reduce confounding due to risk 
factors which vary over time. Since the risk of MVC is strongly age-dependent, 
and the period of available follow-up for some individuals was long (up to 
approximately 15 years) the data were further stratified by three-year age 
group, by which the analysis was adjusted. The choice of three-year age bands 
was purely pragmatic Ȃ the xtpoisson estimator in STATA can only operate on a 
maximum of 500,000 lines of data and any finer subdivision would have 
exceeded this limit. Consideration was also given to the possibility of adjusting 
by calendar year as MVC rates were known to vary over time, and prescribing 
practice for the medications of interest might also have changed over the period 
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of follow-up, however a time adjustment would be collinear with age for each 
individual, so the age-adjustment would implicitly account for most such 
changes. In addition, further stratification of the datasets would have breached 
the limits described previously. 99 percent confidence intervals were calculated 
for each incidence rate ratio in view of the multiple hypotheses being tested. 
Using a sample size formula based on the signed root likelihood ratio (proposed 
by Musonda et al (62) ) it was estimated that 3,169 exposed cases would be 
required in order to detect an incidence rate ratio of 1.2 in the first 28 days after 
prescription, with 95 percent power and at the 5 percent significance level. 
 
Results 
49,821 individuals with a first recording of involvement in a MVC during the 
qualifying period of follow-up were identified (Figure 20). The median duration 
of follow-up in this population was 9.6 years. Table 16 shows the results of the 
case-series analyses, adjusted for age. All categories of medication show a 
marked association with involvement in a MVC in the 28 days up to and 
including the date of first prescription of a course of treatment, consistent with 
the issue of prescriptions as a consequence of involvement in a MVC. 
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Figure 20: Age and sex-specific breakdown of the case-series population 
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Table 16: Age-adjusted incidence rate ratios for involvement in motor vehicle 
crashes, by use of medication 
 
Table 17 shows the equivalent results for individuals exposed to PPIs. No 
significant increased risk of MVCs was observed in any time period for any 
Medication 
Number of 
exposed 
cases * 
,QFLGHQFHUDWHUDWLR&RQILGHQFHLQWHUYDO   
Period 2 Period 3 Period 4 Period 5 Period 6 
            
Benzodiazipenes (all) 10,667 16.44; 15.29, 17.67 1.94 ; 1.62, 2.32 2.38 ; 2.01, 2.81 1.22 ; 1.07, 1.40 1.07 ; 0.92, 1.24 
  Diazepam 7,337 21.02; 19.35, 22.82 1.93 ; 1.54, 2.43 2.77 ; 2.20, 3.48 1.17 ; 0.99, 1.40 1.08 ; 0.89, 1.30 
  Temazepam 3,917 8.71 ; 7.49, 10.14 1.56 ; 1.12, 2.17 1.36 ; 1.02, 1.80 1.16 ; 0.93, 1.46 0.89 ; 0.67, 1.17 
  Nitrazepam 610 3.90 ; 2.18, 6.95 1.66 ; 0.72, 3.86 1.55 ; 0.89, 2.70 1.17 ; 0.64, 2.13 1.07 ; 0.54, 2.10 
  Chlordiazepoxide 538 3.42 ; 2.00, 5.85 1.45 ; 0.65, 3.21 1.36 ; 0.62, 2.99 0.45 ; 0.19, 1.03 1.45 ; 0.87, 2.43 
            
Non-EHQ]RGLD]LSHQHK\SQRWLFVDOOÁ 3,899 6.97 ; 5.96, 8.16 1.06 ; 0.73, 1.54 1.37 ; 1.05, 1.79 0.95 ; 0.75, 1.21 1.11 ; 0.88, 1.41 
  Zopiclone 3,280 6.93 ; 5.83, 8.24 1.03 ; 0.68, 1.55 1.40 ; 1.04, 1.87 0.92 ; 0.70, 1.20 1.21 ; 0.94, 1.55 
  Zolpidem 774 5.31 ; 3.55, 7.95 1.04 ; 0.43, 2.48 1.16 ; 0.60, 2.25 1.13 ; 0.67, 1.89 0.71 ; 0.36, 1.39 
            
Beta-blockers (all) 7,852 2.10 ; 1.74, 2.52 1.00 ; 0.77, 1.30 0.97 ; 0.87, 1.10 0.94 ; 0.79, 1.12 0.97 ; 0.80, 1.17 
  Propranolol 4,344 2.63 ; 2.09, 3.31 1.05 ; 0.73, 1.49 0.89 ; 0.70, 1.14 0.96 ; 0.77, 1.20 0.95 ; 0.74, 1.20 
  Atenolol 3,405 1.67 ; 1.21, 2.30 0.99 ; 0.66, 1.49 0.96 ; 0.82, 1.11 0.83 ; 0.61, 1.12 0.92 ; 0.65, 1.30 
            
Opioids (all) 8,603 10.90 ; 9.96, 11.93 1.70 ; 1.39, 2.08 1.29 ; 1.08, 1.54 1.02 ; 0.87, 1.20 0.90 ; 0.75, 1.08 
  Dihydrocodeine 3,735 11.73 ; 10.21, 13.49 1.60 ; 1.14, 2.25 1.05 ; 0.78, 1.42 1.15 ; 0.91, 1.47 1.03 ; 0.79, 1.35 
  Tramadol 3,153 9.17 ; 7.81, 10.77 1.46 ; 1.02, 2.11 1.34 ; 1.02, 1.76 0.92 ; 0.69, 1.22 0.91 ; 0.67, 1.24 
  Codeine Phosphate 3,081 10.90 ; 9.33, 12.74 1.61 ; 1.11, 2.32 1.33 ; 0.88, 2.00 0.93 ; 0.69, 1.24 0.85 ; 0.62, 1.18 
  Morphine 484 3.14 ; 1.60, 6.15 1.16 ; 0.39, 3.45 0.87 ; 0.43, 1.75 1.10 ; 0.49, 2.47 1.42 ; 0.63, 3.16 
            
Compound analgesics (all) § 21,787 21.22 ; 20.27, 22.20 2.06 ; 1.84, 2.32 2.66 ; 2.40, 2.95 1.10 ; 1.00, 1.21 0.94 ; 0.85, 1.05 
  Co-proxamol 11,775 17.41 ; 16.27, 18.64 1.78 ; 1.49, 2.13 2.24 ; 1.93, 2.59 1.18 ; 1.04, 1.34 0.98 ; 0.85, 1.14 
  Co-dydramol 9,942 20.44 ; 19.06, 21.92 1.76 ; 1.44, 2.15 2.02 ; 1.67, 2.45 0.97 ; 0.83, 1.14 0.84 ; 0.70, 1.00 
  Co-codamol 8,734 15.50 ; 14.30, 16.80 1.62 ; 1.30, 2.01 1.76 ; 1.40, 2.20 0.90 ; 0.76, 1.07 0.93 ; 0.78, 1.11 
            
SSRIs (all) 11,301 1.71 ; 1.47, 1.99 0.92 ; 0.75, 1.12 1.16 ; 1.06, 1.28 1.03 ; 0.92, 1.16 1.02 ; 0.89, 1.16 
  Fluoxetine 5,980 1.31 ; 1.02, 1.69 0.77 ; 0.56, 1.07 1.18 ; 1.02, 1.37 1.00 ; 0.84, 1.19 0.98 ; 0.81, 1.18 
  Citalopram 3,933 1.73 ; 1.26, 2.38 1.02 ; 0.68, 1.53 1.18 ; 0.97, 1.45 0.94 ; 0.72, 1.23 1.14 ; 0.88, 1.49 
  Paroxetine 3,102 1.84 ; 1.38, 2.46 1.01 ; 0.69, 1.48 1.18 ; 0.98, 1.42 1.08 ; 0.86, 1.35 0.88 ; 0.68, 1.14 
            
Tricyclic antidepressants (all) 9,984 2.89 ; 2.52, 3.30 0.92 ; 0.73, 1.16 1.04 ; 0.91, 1.18 0.93 ; 0.81, 1.07 0.95 ; 0.81, 1.10 
  Amitryptyline 5,426 3.35 ; 2.81, 3.99 0.86 ; 0.62, 1.20 0.94 ; 0.77, 1.14 0.85 ; 0.69, 1.05 1.00 ; 0.82, 1.23 
  Doselupin 4,066 2.60 ; 2.03, 3.33 0.98 ; 0.66, 1.45 1.03 ; 0.83, 1.28 0.94 ; 0.74, 1.20 0.78 ; 0.59, 1.02 
  Lofepramine 1,719 1.53 ; 0.91, 2.58 1.09 ; 0.59, 2.01 1.11 ; 0.76, 1.61 1.10 ; 0.76, 1.57 1.07 ; 0.73, 1.56 
  Trazodone 612 2.00 ; 0.96, 4.15 0.61 ; 0.17, 2.24 1.06 ; 0.62, 1.82 0.85 ; 0.43, 1.69 1.13 ; 0.60, 2.11 
            
Antihistamines (all) 14,333 1.16 ; 1.00, 1.35 1.01 ; 0.86, 1.19 1.21 ; 1.04, 1.41 1.02 ; 0.92, 1.12 1.13 ; 1.03, 1.25 
  Loratadine 4,910 1.21 ; 0.90, 1.62 1.00 ; 0.73, 1.38 1.20 ; 0.88, 1.64 1.08 ; 0.90, 1.30 1.13 ; 0.94, 1.36 
  Cetirizine 4,304 1.00 ; 0.72, 1.38 1.06 ; 0.78, 1.44 1.04 ; 0.77, 1.39 0.95 ; 0.78, 1.15 0.93 ; 0.75, 1.14 
  Terfenadine 3,827 0.98 ; 0.65, 1.50 1.02 ; 0.68, 1.53 0.91 ; 0.56, 1.48 0.98 ; 0.77, 1.24 1.07 ; 0.85, 1.35 
  Chlorphenamine 3,092 0.89 ; 0.56, 1.44 0.65 ; 0.37, 1.13 0.92 ; 0.45, 1.87 0.99 ; 0.76, 1.30 1.15 ; 0.88, 1.48 
  Fexofenadine 1,845 1.11 ; 0.69, 1.78 0.92 ; 0.55, 1.53 1.17 ; 0.73, 1.85 1.02 ; 0.76, 1.37 1.39 ; 1.05, 1.83 
  Desloratidine 1,688 1.38 ; 0.90, 2.12 0.93 ; 0.56, 1.55 1.12 ; 0.72, 1.74 0.87 ; 0.63, 1.20 1.25 ; 0.93, 1.68 
  Hydroxyzine 743 2.58 ; 1.44, 4.61 0.74 ; 0.25, 2.13 1.33 ; 0.63, 2.81 1.23 ; 0.74, 2.02 1.36 ; 0.82, 2.23 
  Levocitirizine 480 0.99 ; 0.37, 2.68 2.11 ; 1.06, 4.19 1.14 ; 0.42, 3.11 1.08 ; 0.60, 1.97 0.76 ; 0.35, 1.66 
  Brompheniramine Maleate 474 1.55 ; 0.61, 3.92 1.31 ; 0.49, 3.53 1.62 ; 0.50, 5.19 1.68 ; 0.99, 2.85 1.34 ; 0.73, 2.44 
  Astemizole 451 1.82 ; 0.71, 4.65 1.55 ; 0.57, 4.22 2.45 ; 0.82, 7.34 0.85 ; 0.39, 1.84 1.54 ; 0.86, 2.78 
                        
            
* -  Individual medication totals do not equate to the category total as some subjects received more than one medication in each category.     
- Exposure-time periods: 2)  4 week period up to and including date of prescription       
 3)  4 week period following 1st prescription of a course of treatment       
 4)  remainder of exposed time         
 5)  12-week period following end of exposure        
 6)  second 12 week period following end of exposure        
Á- Zopiclone, zolpidem, chlormezanone, zaleplon.           
§ - Co-codamol, co-proxamol & co-dydramol.            
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medication in this class, suggesting that there is no systematic bias inherent in 
the choice of exposure categories. 
Table 17: Age adjusted incidence rate ratios for involvement in motor vehicle 
crashes among individuals prescribed proton pump inhibitors 
 
Discussion 
This is the largest study to date, with the longest period of follow-up, of the 
effect of taking a selection of prescribed medicines on the risk of involvement in 
a motor vehicle crash. The results suggest that the risk of MVC may be increased 
by the use of benzodiazepines, opioids such as codeine phosphate, 
dihydrocodeine and tramadol, and compound analgesic preparations containing 
paracetamol and an opioid for the duration of their usage, but not by the use of 
morphine. In addition, there was a modest association between involvement in 
a MVC and the use of non-benzodiazepine hypnotics, SSRIs and antihistamines 
for longer than four weeks. No evidence was found of any increased risk of MVC 
among users of tricyclic antidepressants or beta-blockers, or following 
withdrawal from any of the medications under investigation. 
Medication Period 2 Period 3 Period 4 Period 5 Period 6
Proton pump inhibitors (all) 8,391 1.79 (1.50 - 2.14) 0.91 (0.72 - 1.16) 1.11 (0.97 - 1.26) 1.11 (0.96 - 1.28) 0.99 (0.84 - 1.18)
  Lansoprazole 4,957 1.93 (1.53 - 2.44) 0.69 (0.47 - 1.01) 1.03 (0.86 - 1.23) 1.01 (0.82 - 1.23) 0.93 (0.74 - 1.18)
  Rabeprazole 4,165 0.95 (0.46 - 1.97) 0.66 (0.28 - 1.56) 1.26 (0.86 - 1.85) 0.71 (0.42 - 1.20) 0.91 (0.55 - 1.50)
  Pantoprazole 1,144 2.33 (1.22 - 4.45) 1.51 (0.68 - 3.35) 1.51 (0.91 - 2.50) 1.09 (0.60 - 1.99) 0.70 (0.32 - 1.56)
  Omeprazole 633 1.42 (1.05 - 1.92) 0.95 (0.66 - 1.37) 1.04 (0.86 - 1.27) 1.28 (1.05 - 1.57) 1.04 (0.82 - 1.33)
  Esomeprazole 629 2.19 (1.16 - 4.12) 1.94 (0.99 - 3.78) 1.06 (0.65 - 1.73) 0.95 (0.51 - 1.77) 1.10 (0.57 - 2.10)
Į,QGLYLGXDOPHGLFDWLRQWRWDOVGRQRWHTXDWHWRWKHFDWHJRU\WRWDODVVRPHVXEMHFWVUHFHLYHGPRUHWKDQRQHPHGLFDWLRQLQHDFKFDWHJRU\
ȕ([SRVXUHWLPHSHULRGV 2)  4 week period up to and including date of prescription
3)  4 week period following 1st prescription of a course of treatment
4)  remainder of exposed time
5)  12-week period following end of exposure
6)  second 12 week period following end of exposure
Number of 
exposed casesĮ
Incidence rate ratio (99% Confidence interval)ȕ
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Adequately powered studies of the effect of taking prescribed medicines on the 
risk of MVC are scarce, possibly due to the difficulty of obtaining a sufficiently 
large number of MVC cases and detailed information on their use of medication. 
The use of primary care data in this study provides considerable statistical 
power to investigate these associations, above and beyond that which would be 
available from any other source. The use of the self-controlled case series 
method circumvents the problem of selecting an appropriate control group and 
eliminates the effect of fixed (per individual) confounding (63). An additional 
benefit is the ability to explore temporal changes in risk during exposure to the 
medications of interest, or following the cessation of treatment; factors which 
have not been investigated before. 
This study is subject to a number of limitations which must be considered when 
interpreting the results. A substantial number of hypotheses have been 
investigated, increasing the risk that spurious associations might have been 
observed, although the use of 99% confidence intervals mitigates against this 
possibility.  The use of the case-series analysis in large healthcare datasets 
establishes the temporal relation between the prescription of a medication and 
an outcome e.g. MVC, but cannot distinguish between the clinical impact of the 
disease which necessitated the prescription of the medication and the side-
effects of the drug itself. In either case, the observed increased risks are useful 
in informing practitioners and patients of the potential consequences of driving 
whilst using, or needing to use, the medications in question. The lack of 
regularly updated information on lifestyle exposures in the THIN data makes it 
impossible to exclude confounding by factors which accompany the issue of a 
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prescription; for example an increase in alcohol consumption might occur in 
patients suffering depressive illness and therefore confound the observed 
association with the use of SSRIs. It is also impossible to determine whether 
patients collected their medication or took it as prescribed, so the results give a 
guide to the consequences of receiving a prescription, rather than taking the 
medication per se.  
The lack of detailed information on the duration of treatment is also 
problematic, and may have led to misclassification of exposed time periods. For 
example, some prescriptions may be for as short a period as one to two weeks, 
leading to an underestimate of the risks associated with short term use. For 
similar reasons, it was also impossible to investigate whether dose-response 
relationships were present in this population. 
A further issue, inherent in all studies of MVCs in THIN, is the quality of 
recording of these events in primary care. The inability to differentiate between 
drivers, passengers and pedestrians tends to dilute the observed effects, and the 
possibility (discussed earlier) that accidents resulting in injury may not be 
coded as MVCs raises the possibility that the observed associations describe the 
risks of involvement in a subset of more minor MVCs, rather than the overall 
population-level risk.  
It is possible that patients seeking treatment for other illnesses for which the 
medications of interest are eventually prescribed may report some minor 
events which would not otherwise have been recorded, however if this were a 
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serious issue one would expect to observe increased incidences of MVC for all 
medications. In fact, there was no increased incidence of MVC among users of 
beta-blockers and tricyclic antidepressants (although interpretation of the 
result for the beta-blockers is problematic, as discussed earlier). Finally, it is not 
possible to account for the impact of patient behaviour following the receipt of a 
prescription. Some patients may refrain from driving whilst taking the 
medications of interest, leading to an underestimate of the associated risk. This 
is consistent with the observation that morphine use was not associated with an 
increased risk of injury when all other opioids investigated were, as morphine is 
generally reserved for the management of severe pain, and those receiving such 
treatment may therefore be more likely to be incapable of driving, or to have 
been advised not to drive. 
The four week period prior to drug prescription (Period 2) was designed to 
exclude any MVCs that may have led to a drug prescription for pain control or 
relief from anxiety from the baseline person time. The high rate ratios observed 
in this period unsurprisingly suggest that some of these medications are 
prescribed in response to a MVC. Data were not available on the provision of 
prescriptions from sources other than the primary care centres so there may be 
some misclassification is medication was obtained from other places such as 
emergency doctors or family members. However, this would be expected to 
introduce random error to the analysis which would tend to reduce the size of 
effect seen. 
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The results of previous studies investigating the effect of opioid use on the risk 
of MVC are conflicting. Ray et al (55) found no evidence of an increased risk of 
MVC associated with oral opioid use in a study of 495 injurious crashes among 
16,262 elderly drivers, although as the exact medications concerned are not 
specified, it is possible that the patients concerned may have been using only 
mild or low-dose opioids. By contrast, Leveille et al (51) found that opioid 
(primarily codeine and oxycodone) use was associated with an increased risk of 
MVC (adjusted risk ratio = 1.8) in a case-control study of 681 elderly drivers. 
The observation that the use of these medications is associated with a 70 
percent to 100 percent increased incidence of MVC in the THIN population 
support the latter result and are congruent with previous reports of driving 
impairment due to opioid use (46) and with serological studies which show that 
opioids are commonly detected in the blood of fatally injured drivers (64). 
In common with the study by Barbone et al (49), the THIN data suggest an 
increased incidence of MVC among those taking zopiclone, but in this 
population the effect was only observed following prolonged exposure. There 
was also a modest increased incidence among longer term users of SSRIs which 
was not observed in the earlier study. This could be explained in terms of the 
larger population and longer duration of follow-up (and resultant increased 
statistical power) available in THIN. The use of antihistamines had no 
immediate effect on the risk of MVC, although a small effect was seen after 
longer term use of these drugs, however, the availability of many antihistamines 
without prescription in the UK makes it difficult to derive firm conclusions from 
this result. There was no evidence of an increase in risk of MVC among users of 
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tricyclic depressants. Studies of elderly drivers (51, 55) have shown an increase 
in the risk of MVC in users of these medications, but a larger study in a more 
representative population did not (49). 
The findings in relation to benzodiazepines are consistent with those of 
previous studies (49-55) which suggest that current use of these medications 
approximately doubles the risk of MVC. In the THIN data there was a much 
larger association between diazepam use and MVC than with the use of other 
benzodiazepines. Diazepam is commonly prescribed as an anxiolytic (65) and 
taken during the daytime when individuals are more likely to drive, whereas 
temazepam and nitrazepam are more likely to be used as night-time hypnotics. 
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Conclusions 
The results of this study suggest that there is a substantially increased incidence 
of MVC among those taking opioids such as dihydrocodeine, codeine phosphate 
and tramadol and among those taking combined acetaminophen and opioid 
analgesics. There was also some evidence of an increased incidence of MVC 
among those taking SSRIs and antihistamines for long periods, which merits 
further investigation. In addition, this work confirms previous findings of an 
association between the use of benzodiazepines and zopiclone and an increased 
risk of MVC. There was no evidence of an association between the therapeutic 
use of tricyclic antidepressants or beta-blockers and MVC. 
The results of this study suggest that a substantial number of injuries could be 
prevented if users of certain medications were to refrain from driving. Further 
work is required to explore these relationships further, with particular 
emphasis on the mechanisms involved. 
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6. THE IMPACT OF DISORDERED SLEEP ON THE 
RISK OF MOTOR VEHICLE CRASHES ʹ A CASE-
CONTROL STUDY 
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Abstract 
Background.  Sleep apnoea syndromes are an established risk factor for 
involvement in motor vehicle crashes (MVCs), but the potential impact of other 
sleep disorders has received little attention in the literature.  
Study design and methods. Data from THIN were used to conduct a nested 
case-control study of the effects of snoring, sleep apnoea syndromes and 
insomnia on the risk of MVC 
Results  Insomnia was associated with an increased risk of involvement in 
MVC (Odds Ratio =1.57; 99% Confidence Interval: 1.45 to 1.69), as were snoring 
(OR=1.91; 99%CI: 1.52 to 2.40) and sleep apnoea syndromes (OR=1.68; 99%CI: 
1.08 to 2.61).  These associations were independent of the effects of alcohol 
consumption and the use of sedative and antidepressant medications. 
Conclusions.  The results of this study suggest that insomnia is a potential risk 
factor for involvement in MVCs, and confirm previous findings that snoring and 
sleep apnoea syndromes are associated with an increased crash risk. 
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Introduction 
Research in the UK suggests that up to 23% of MVCs in the United Kingdom may 
be caused by drivers falling asleep whilst driving (66). Sleep apnoea syndromes 
are an established risk factor for involvement in MVCs (67), and there is limited 
evidence to suggest that non-apnoeic snorers may also be at increased risk (68). 
In addition, an association between irregular sleep patterns and an increased 
risk of involvement in MVCs among occupational drivers has been reported 
(69), but the effect of insomnia on the risk of MVC in the general population has 
received relatively little attention in the literature. A 1991 telephone survey in 
the United States reported that 5% of individuals with symptoms of insomnia 
had been involved in a MVC due to sleepiness compared with 2% in the wider 
population, suggesting that difficulty sleeping may more than double the risk of 
such crashes (70), however these figures were not adjusted for the use of 
sedative or antidepressant medications, which have been demonstrated to 
increase the risk of involvement in MVCs (see pp. 78 to 102). This study uses 
data from THIN to investigate the association between sleeping disorders 
recorded in primary care records and subsequent involvement in MVCs, 
adjusting for the effects of current treatment with sedative or antidepressant 
medications, and of alcohol consumption. 
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Methods 
Study design and population 
Data from THIN were used to construct a nested case-control population. Cases 
were defined as all individuals with a first Read Term recording indicating 
involvement in a MVC dated after the 1st January 1991, at least one year after 
the start of their computerised medical record and whilst they were aged 
between 18 and 75 years. MVCs recorded prior to 1991 were excluded as MVC 
incidence rates in THIN rise steeply from approximately nil to a relatively 
steady level between the start of computerised follow-up and 1990, indicating 
that MVCs may not be consistently recorded within each practice prior to this 
time. As before, the age range was chosen to minimise the proportion of cases 
who are unlikely to be drivers, and recordings in the first year of computerised 
follow-        ǲǳ Ǥ The 
control population was randomly selected from those individuals with no 
recorded MVC, matched by age (±2 years), sex and practice. Each control was 
required to have a minimum of 1 year of computerised medical recording 
before the date of MVC of their associated case, and to be from a different 
household. Where possible, 2 controls were matched to each case. 
Exposure definitions 
The Read Term dictionary was searched using SearchRC to identify all terms 
and categories containing the terms *insom*, *snor*, *sleep*, *apnoe* and 
*apne*. The resulting list was hand searched to identify relevant terms. Terms   ǡ       ȋǲ ǳ
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terms) were excluded. Individuals were defined as suffering from sleep apnoea 
syndromes (including both obstructive and neurological apnoeas), insomnia or 
snoring if their medical or AHD table records contained a relevant record at any 
time prior to the date of MVC.  
Exposure to sedative medication was defined as the presence or absence of 
therapy table entry indicating a prescription for any benzodiazepine or other 
hypnotic (zopiclone, zolpidem, chlormezanone or zaleplon) dated up to 16 
weeks prior to the date of MVC, but not on the date of MVC (the rationale for 
choosing this time period is the same as in the preceding chapter). Exposure to 
antidepressant medication was defined as the presence or absence of a 
prescription for any tricyclic antidepressant or selective serotonin reuptake 
inhibitor within the same period.  
Levels of alcohol consumption were determined using records from both the 
medical and AHD tables. The Read Term list was searched (using SearchRC) to 
identify all terms and categories containing the keywords *alcoh* or *drink*. 
The resulting list was manually searched to identify those terms indicating a 
specific level of alcohol consumption. The medical and AHD table records for all 
individuals were searched to identify the most recent record prior to the date of 
MVC containing any of these codes. In addition, the AHD table records were 
searched to identify the most recent (but prior to the date of MVC) directly 
entered (numeric) recordings of alcohol consumption for each individual. These 
data were transformed into categories equivalent to those indicated by the 
Read Terms for alcohol consumption and combined with the Read Term based 
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records to allow the most recent overall recordings to be identified. The 
categories obtained were: none; <1 unit / day; 1-2 units /day; 3-6 units/day; 7-
9 units/day; and >9 units/day. 
In order to determine whether any observed association between disordered 
sleep and MVC might occur as a consequence of individuals with poor general 
health consulting their GP more often (and therefore being more likely to report 
both the existence of sleep-related symptoms, or involvement in a MVC), 
frequencies of consultation were calculated for each individual in the study 
population. The frequency of consultation was defined as the number of dates 
on which data were entered in each ǯmedical table records 
prior to the date of MVC (excluding those on which recordings relating to the 
presence of any of the sleep disorders of interest were entered), and more than 
one year after the start of the computerised record, divided by the duration of 
this period. Recordings in the therapy table were excluded as repeat 
prescriptions may be issued without a formal consultation. 
Statistical methods 
The data were analysed using conditional logistic regression models in STATA 
9.1 (STATA Corp. TX, United States) for Windows XP. Three analyses were 
conducted; a univariate analysis of the association between each sleep disorder 
and MVC, an analysis adjusted for the current use of sedative or antidepressant 
medications, and an analysis adjusted for medication use and alcohol 
consumption (for those individuals with a recording of alcohol consumption). 
The adjusted results were also stratified according to consultation frequency 
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(above vs. below or equal to the median frequency)_to investigate the impact of 
consulting behaviour on the results. In view of the multiple hypotheses being 
tested, 99% confidence intervals were calculated to reduce the probability of 
observing positive associations due to chance. 
A power calculation using PS (71) for Windows XP indicated that 14,000 cases 
would provide over 95% power at the 1% significance level to detect a 30% 
increase in the risk of MVC due to insomnia (well below the level in the US 
survey), assuming a background prevalence of insomnia of 3% (72). 
Results 
The basic demographic characteristics of the study population are given in 
Table 18. The case and control populations were similar in terms of age and 
socioeconomic status. 5.3%, 0.6% and 0.2% of cases had diagnoses of insomnia, 
snoring and sleep apnoea syndromes respectively recorded in the THIN 
database. 
Insomnia was associated with an increased risk of involvement in a MVC 
(OR=1.57; 99% CI: 1.45 to 1.69). Adjustment for the use of sedative and 
antidepressant medications (OR=1.49; 99% CI: 1.38 to 1.62) and alcohol 
consumption (OR=1.41; 99%CI: 1.26 to 1.57) slightly reduced the observed 
effects, but the association remained significant (Table 19). Snoring (OR=1.91; 
99% CI: 1.52 to 2.40) and sleep apnoea syndromes (OR=1.68; 99% CI: 1.08 to 
2.61) were associated with increased risks of MVC, which were unaffected by 
adjustment for medication use and alcohol consumption
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Table 18: Socio-demographic characteristics and prevalence of sleep disorders 
among individuals involved in MVCs and age & gender matched controls in THIN 
255 (November 2004) 
 
 
Table 19: Crude and adjusted associations between involvement in MVCs and 
sleep disorders in THIN 255 (November 2004) 
 
males females males females
n =19,954 n =20,155 n =37,908 n =38,490
Age at time of MVC, median (interquartile range) 36 (27 - 48) 36 (27 - 49) 36 (27 - 49) 37 (27 - 50)
Quintile of Townsend deprivation index, n (%)
  1st; least deprived 4,641 (23.3) 5,107 (25.3) 8,569 (22.6) 9,152 (23.8)
  2nd 4,058 (20.3) 4,196 (20.8) 7,191 (19.0) 7,505 (19.5)
  3rd 3,941 (19.8) 3,989 (19.8) 7,291 (19.2) 7,498 (19.4)
  4th 3,678 (18.4) 3,606 (17.9) 6,841 (18.1) 6,851 (17.8)
  5th; most deprived 3,006 (15.1) 2,638 (13.1) 6,265 (16.5) 5,808 (15.1)
  not available 630 (3.2) 619 (3.0) 1,751 (4.6) 1,676 (4.4)
Sleep disorders recorded prior to MVC, n (%)
  insomnia 777 (3.9) 1,343 (6.7) 1,048 (2.8%) 1,645 (4.3)
  snoring 199 (1.0) 54 (0.3) 184 (0.5%) 74 (0.2)
  sleep apnoea syndromes 53 (0.3) 11 (0.1) 58 (0.2) 15 (0.0)
Medication use up to 112 days prior to MVC, n (%)
  benzodiazepines 401 (2.0) 735 (3.7) 657 (1.7) 1,050 (2.7)
  non-benzodiazepine hypnotics 112 (0.6) 194 (1.0) 209 (0.6) 314 (0.8)
Alcohol consumption prior to MVC, n (%)
  none 1,604 (8.0) 2,647 (13.1) 2,742 (7.2) 4,844 (12.6)
  <1 unit / day 4,610 (23.1) 8,543 (42.4) 8,193 (21.6) 14,914 (38.8)
  1-2 units / day 3,805 (19.1) 2,313 (11.5) 7,280 (19.2) 4,873 (12.7)
  3-6 units / day 1,680 (8.4) 367 (1.8) 3,176 (8.4) 793 (2.1)
  7-9 units / day 36 (0.2) 10 (0.1) 84 (0.2) 13 (0.0)
  >9 units / day 8 (0.0) 1 (0.0) 26 (0.1) 2 (0.0)
  not recorded 8,211 (41.2) 6,274 (31.1) 16,407 (43.3) 13,051 (33.9)
Characteristic
Cases Controls
Unadjusted model
Adjusted for use of sedative 
and/or antidepressant 
medications
Adjusted for medication use* 
and alcohol consumption
Insomnia 1.57 (1.45 - 1.69) 1.49 (1.38 - 1.62) 1.41 (1.26 - 1.57)
Sleep Apnoea 1.68 (1.08 - 2.61) 1.67 (1.07 - 2.59) 1.61 (0.90 - 2.87)
Snoring 1.91 (1.52 - 2.40) 1.90 (1.51 - 2.39) 1.85 (1.37 - 2.49)
ncases=40,109 ncases=40,109 ncases=21,810
ncontrols=76,318 ncontrols=76,318  ncontrols=33,441
* Sedative and/or antidepressant medications
Condition
OR (99% Confidence Interval)
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Table 20 shows the results of the adjusted analysis, stratified by consultation 
frequency. Effect sizes for insomnia and sleep apnoea were similar in both 
groups, but the effect size for snoring was greatest among those with below 
median consultation frequencies.  
Table 20: Association between involvement in MVCs and sleep disorders in THIN 
255 (November 2004), adjusted by use of sedative and antidepressant 
medications and alcohol consumption and stratified by consultation frequency 
 
 
Discussion 
The results of this study indicate that practitioner-recorded insomnia is 
associated with a 1.5-fold increase in the risk of MVC, and that this effect is not 
explained by the use of sedative medications amongst affected individuals. The 
observed associations between both snoring and sleep apnoea syndromes and 
subsequent involvement in MVCs are consistent with previous reports in the 
literature (67, 68) suggesting that the use of THIN data to investigate the impact 
of disordered sleep on the risk of MVC is appropriate. 
Below median 
consultation 
frequency
Above median 
consultation 
frequency
Snoring 2.54 (1.11 to 5.80) 1.29 (0.85 to 1.95)
Insomnia 1.10 (0.69 to 1.75) 1.27 (1.10 to 1.46)
Sleep Apnoeas 1.49 (0.26 to 8.54) 1.65 (0.75 to 3.67)
Condition
Odds Ratio (99% Confidence interval)
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The results of the analysis stratified by consultation frequency suggest that the 
association between snoring and MVC was largely driven by those consulting 
their GP the least frequently, whilst the associations between sleep apnoea and 
insomnia and MVC were broadly similar in both groups. This may have 
occurred because snoring is more likely to be the primary reason for a 
consultation among those who do not consult their GP frequently, and the 
severity (and any consequent effects on driving ability) may be greater in this 
group. The absence of such a marked difference in effect sizes for insomnia and 
sleep apnoea suggests that these conditions are more likely to be the primary 
reasons for a consultation and that bias due to opportunistic recording during 
consultations for other conditions or problems is minimal. 
As before, the major strength of this study is the considerable statistical power 
provided by the use of THIN; this is the largest study to date of these effects in 
the UK population. The study population contained a reasonable spread of 
socio-demographic characteristics, and the case and control populations were 
well matched in terms of age, sex and deprivation, suggesting that the results 
should be generalisable to the overall UK population. In addition, the 
availability of prescription data permits adjustment for the effects of sedative 
and antidepressant medications which may also affect MVC risk. Fortunately, in 
this population, a substantial proportion of individuals experiencing disordered 
sleep did not receive medication so the effects were not completely co-linear 
and the adjustment should be adequate. 
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The major limitation of this study is the uncertainty as to whether individuals 
involved in MVCs in the study population were driving at the time. Assuming 
that passengers and / or pedestrians are not also more likely to be involved in 
MVCs as a consequence of disordered sleep, their presence in the study 
population would tend to lead to underestimation of the true magnitude of 
association. It is also likely that the recording of sleep disorders in THIN under-
represents the true prevalence in the UK population, as approximately only one 
in four individuals with insomnia inform their physician (51), and the 
prevalence of sleep apnoea syndromes in the UK may be as high as 3.8% (73) - 
well above the observed level in this study (although this may be in part due to 
the relative youth of individuals involved in MVCs compared with the general 
population). It is likely that those individuals who consult their physician 
regarding sleep disorders are those with more severe symptoms, so the 
observed effects may overestimate the risk of MVC associated with these 
conditions as a whole, whilst underestimating the absolute number of 
individuals affected. The poor recording of alcohol consumption in this 
population is problematic as it prevents full adjustment for any potential 
confounding effect of higher consumption of alcohol among individuals with 
sleep disorders, although the similarity of the adjusted effects in the sub-
population with a record of alcohol consumption to those in the wider 
population is reassuring.  
Sleep apnoea syndromes cause daytime hypersomnolence  (74), and are an 
established risk factor for involvement in MVCs, with estimates of the odds ratio 
of association ranging from 1.3 to 13.3 (67). The observation that sleep apnoea 
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syndromes are associated with a 1.6-fold increased risk of MVC in the THIN 
population is consistent with these findings, but at the lower end of the range, 
suggesting that the presence of non-drivers in the population may indeed dilute 
the observed effects somewhat. Treatment with continuous positive airway 
pressure has been demonstrated to reduce the risk of MVC among affected 
individuals (67), providing strong evidence that the association is causal. 
The results of this study support the limited available evidence suggesting that 
snoring is associated with an increased risk of involvement in MVC (68). 
Snoring is associated with daytime hypersomnolence (75), and as many as 36% 
of adults aged 30 to 60 years may be habitual snorers (75). The emergence of 
snoring as a potential risk factor for involvement in MVCs is of concern and 
merits further investigation given the high prevalence of snoring in the general 
population. It is likely that some of the association between snoring and 
involvement in MVCs in this study is due to the presence of individuals with 
undiagnosed sleep apnoea syndromes presenting with the symptom of snoring, 
but regardless of the causal pathways involved snoring appears to be an 
important risk factor for MVCs. 
Individuals with insomnia report a range of daytime symptoms with the 
potential to affect driving performance, including hypersomnolence, irritability 
and impaired memory and cognitive function (69, 76-78).  It is therefore 
plausible that the association between insomnia and involvement in MVCs in 
the THIN population is causal. The only previous report in the literature on the 
association between insomnia and risk of involvement in a MVC in the general 
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population is from a telephone survey in the United States (70). This suggested 
that individuals with insomnia had a 2.5-fold increased risk of involvement in a 
MVC although the absence of both formal statistical analysis and adjustment of 
for potential confounding factors such as the use of sedative medication makes 
interpretation of these results problematic. 
Conclusion 
The findings of this study corroborate previously observed associations 
between snoring and sleep apnoea syndromes and an increased risk of 
involvement in MVCs. In addition, they demonstrate an increased risk of 
involvement in MVCs among individuals reporting insomnia to their physician, 
which is independent of the effect of the use of sedative medications. If these 
associations are causal, effective management of these heterogeneous sleep 
disorders may reduce the risk of involvement in MVCs. 
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7. THE RISK OF MOTOR VEHICLE CRASHES 
AMONG INDIVIDUALS WITH DIABETES MELLITUS 
ʹ A CASE-CONTROL STUDY 
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Abstract  
Background. Individuals with diabetes may be subject to driving restrictions in 
the United Kingdom (UK), but few studies have assessed the impact of diabetes 
on the risk of involvement in motor vehicle crashes (MVCs) in the UK 
population. 
Study design and methods. Data from THIN were used to conduct a nested 
case-control study of the effect of diabetes on the risk of MVC, stratified by 
treatment group. 
Results. 40,109 individuals aged 18-75 years with a first recorded motor 
vehicle crash on or after 1st Jan 1991 and 76,398 controls (matched by age, sex 
and primary care provider)were identified. Following adjustment for frequency 
of GP consultation, a diagnosis of diabetes was associated with a decreased risk 
of involvement in a MVC (Odds Ratio Ȃ 0.78; 95% Confidence Interval, 0.72 to 
0.85). The risk of involvement in a MVC was similar for individuals receiving 
insulin treatment, oral antidiabetics and for those receiving no medication. 
Conclusions. A population-based assessment suggests that the risk of 
involvement in MVC is lower among individuals with diabetes than in the 
general UK population.  
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Introduction 
Diabetes mellitus affects over 170 million individuals worldwide, and 
demographic changes are projected to double the number of cases by 2030 
(79). Hypoglycaemia due to diabetes is often cited as a cause of motor vehicle 
accidents (80), and as a consequence many drivers with diabetes are charged 
higher premiums by their motor insurers (81). 
The evidence base supporting an effect of diabetes mellitus on the risk of 
involvement in MVC in the UK is limited. Two comparative studies in the UK 
found no significant increase in the risk of motor vehicle crashes (MVCs) among 
individuals with insulin-treated diabetes (82, 83); however both were based on 
very small numbers of crashes among drivers with diabetes and may have 
lacked sufficient power to detect any real association. By contrast, the largest 
study to date, an audit of United States (US) police records, suggests that drivers 
with diabetes are 44% more likely than other drivers to be involved in an 
accident where they are found to be at fault (84). Studies elsewhere in the 
world have produced conflicting results, with some suggesting that drivers with 
diabetes are at an equal or even decreased risk of MVC relative to the general 
population (85-87), whilst others suggest that the risk is increased (88-90). 
These inconsistencies are at least partly due to methodological issues (91), but 
may also reflect differences in driving conditions, behaviours and regulations in 
different jurisdictions.  
Current United Kingdom driving regulations impose restrictions on individuals 
who use insulin treatment, but do not apply to those using oral antidiabetic 
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medications or diets to control their condition unless they also suffer from 
complications which may impair driving performance. This is a potential 
concern, as hypoglycaemia may also occur among individuals using oral 
antidiabetic medications (92), and chronic hyperglycaemia (which may occur in 
those with diet controlled diabetes) may result in cognitive impairment (93-
95). This study uses data from THIN to assess whether whether individuals 
with diabetes, stratified by treatment group, are at increased risk of 
involvement in motor vehicle crashes (MVCs) compared with the general 
population. 
Methods 
Study population 
Data from THIN were used to construct a nested case-control population. Cases 
were defined as all individuals with a first Read Term indicating involvement in 
a MVC dated after the 1st January 1991, at least 1 year after the start of their 
computerised medical record and whilst aged 18-75 years. The reasons for 
these criteria were the same as in the previous chapter. The control population 
was randomly selected from those individuals with no recorded MVC, matched 
by age (±2 years), sex and practice. Each control was required to have a 
minimum of 1 year of computerised medical recording before the date of MVC 
of their associated case, and to be living in a different household to the case. 
Where possible, 2 controls were matched to each case. 
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Exposure ascertainment 
The Read Term dictionary was searched using SearchRC to identify all terms 
and categories containing the terms *diab* and *glycae*. The resulting list was 
manually inspected to identify all terms indicating the presence of chronic 
diabetes. Terms relating to gestational diabetes were excluded as this condition 
normally resolves post partum. The medical table records of all individuals in 
the study population were searched to identify relevant diagnoses dated prior 
to the date of MVC. The therapy table records of all individuals were searched to 
identify prescriptions for insulin or antidiabetic medications up to 1 year prior 
to the date of MVC. Individuals were defined as currently insulin dependent if 
they were diagnosed with diabetes and were treated with insulin. Individuals 
were classified as on antidiabetic therapy if they were diagnosed with diabetes 
and treated with antidiabetic drugs, but not insulin (in line with the 
categorisation used by the UK licensing authority (96)). Those with diagnosed 
diabetes but with no prescribed treatment within one year prior to the date of 
MVC were classified as untreated. To obtain an objective marker of glucose 
control, the AHD records of all individuals with a diagnosis of diabetes were 
searched to identify the results of glycosylated haemoglobin (HbA1c) 
measurements within 1 year prior to the date of MVC. Individuals were 
classified as controlling their diabetes well if the most recent HbA1c 
measurement was 7% or lower, and as controlling their diabetes poorly if their 
HbA1c was greater than 7% (97). Where multiple recordings were available, 
the most recent recording prior to the date of MVC was used. 
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Frequencies of GP consultation were calculated for each individual to permit 
adjustment for the possibility that individuals visiting their GP regularly due to 
chronic disease may be more likely to report a MVC. The frequency of 
consultation was defined as the number of dates on which data were entered in 
each ǯ      prior to the date of MVC, and 
more than one year after the start of the computerised record, divided by the 
duration of this period. Recordings in the therapy table were excluded as repeat 
prescriptions may be issued without a formal consultation. Area level 
Townsend indices    ǯ    
available to allow the socio-economic status of cases and controls to be 
compared.  
Statistical analysis 
The data were analysed using conditional logistic regression models in STATA 
9.1 (STATA Corp. TX, United States) for Windows XP.  Three analyses were 
conducted. The first compared the risk of involvement in MVC for all individuals 
with diabetes with that in the general population. Two further analyses 
subdivided individuals with diabetes by the type of treatment prescribed and by 
their level of diabetic control, respectively. In each case unadjusted odds ratios, 
and odds ratios adjusted by quintile of consultation frequency were calculated. 
In order to further investigate the impact of consulting behaviour the 
association between diabetes and involvement in MVC was also calculated 
stratified according to consultation frequency (above vs. below or equal to the 
median frequency). 
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A power calculation using PS for WindowsXP suggested that 45,000 MVC cases 
would provide over 95% power at the 5% significance level to detect a 15% 
increased risk of involvement in MVC, assuming a background prevalence of a 
diagnosis of diabetes of 3.7% (98). 
Results 
The basic demographic characteristics of the study population are given in 
Table 21.  The case and control populations were similar in terms of age and 
socioeconomic status. The prevalence of diabetes (recorded prior to the date of 
MVC) in the population was 2.8%. 24.4% of individuals with diabetes received a 
prescription for insulin within 1 year prior to the date of MVC, 33.2% received 
only antidiabetic medications, and 42.4% received no prescription. According to 
the most recent available glycosylated haemoglobin measurement, 17.2% of 
individuals with diabetes were controlling their condition well prior to the date 
of Mȋ ? ? ? ?Ȍǡ  ? ?Ǥ ? ?ȋ ? ? ? Ȍǡ   ? ?Ǥ ? ?
had no recording in the year prior to MVC. Individuals involved in MVCs 
consulted their GP more regularly than controls (median numbers of 
consultations per year 2.9 and 1.6 respectively) and women consulted their GP 
more frequently than men (3.1 versus 1.3 consultations per year). 
In the unadjusted analysis, diagnosed diabetes was associated with a small 
increased risk of involvement in MVC (Table 22: OR = 1.12; 95% Confidence 
interval, 1.04 to 1.21). Similar effects were observed in each of the three 
treatment categories, but only the untreated group showed a significantly 
raised risk of involvement in MVC (OR=1.15; 95% CI, 1.03 to 1.29). There was 
 122 
 
little difference between those with well controlled diabetes and poorly 
controlled diabetes. Following adjustment by quintile of GP consultation 
frequency, diagnosed diabetes was associated with a decreased risk of MVC 
(OR=0.78; 95% CI, 0.72 to 0.85). There was little difference in risk between 
those prescribed insulin (OR = 0.71, 95% CI, 0.61 to 0.83) and those taking oral 
antidiabetics (OR = 0.73; 95% CI, 0.64 to 0.84) and those receiving no treatment 
(OR = 0.87; 95% CI, 0.77 to 0.98). Stratification by level of diabetic control (as 
indicated by glycosylated haemoglobin levels) showed similar risks of 
involvement in MVCs among individuals with good control (OR = 0.81; 95% CI, 
0.68 to 0.97) and individuals with poor control (OR = 0.77; 95% CI 0.66 to 0.90). 
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Table 21: Socio-demographic characteristics and prevalence of diabetes among 
individuals involved in motor vehicle crashes and age & gender matched controls 
in THIN 255 (November 2004) 
 
  
Characteristic 
  
Cases 
  
Controls 
  
  males females  males females  
    n =19,954 n =20,155   n =37,908 n =38,490   
         
 Age at time of MVC, median (interquartile range)  36 (27 - 48) 36 (27 - 49)  36 (27 - 49) 37 (27 - 50)  
         
 Quintile of Townsend deprivation index, n (%)        
   1st; least deprived  4,641 (23.3) 5,107 (25.3)  8,569 (22.6) 9,152 (23.8)  
   2nd  4,058 (20.3) 4,196 (20.8)  7,191 (19.0) 7,505 (19.5)  
   3rd  3,941 (19.8) 3,989 (19.8)  7,291 (19.2) 7,498 (19.4)  
   4th  3,678 (18.4) 3,606 (17.9)  6,841 (18.1) 6,851 (17.8)  
   5th; most deprived  3,006 (15.1) 2,638 (13.1)  6,265 (16.5) 5,808 (15.1)  
   not available  630 (3.2) 619 (3.0)  1,751 (4.6) 1,676 (4.4)  
         
 Individuals with a recordiing of diabetes prior to MVC, n (%)  659 (3.3) 539 (2.7)  1075 (2.8) 1004 (2.6)  
   prescribed insulin*  161 (0.8) 130 (0.7)  276 (0.7) 233 (0.6)  
   prescribed antidiabetics*  240 (1.2) 150 (0.7)  389 (1.0) 310 (0.8)  
   untreated*  258 (1.3) 259 (1.3)  410 (1.1) 461 (1.2)  
         
 Level of diabetic control, n (%)        
   good control (HbA1c level <=7  120 (0.6) 93 (0.5)  173 (0.5) 179 (0.5)  
   SRRUFRQWURO+E$FOHYHO!  186 (0.9) 127 (0.6)  278 (0.7) 243 (0.6)  
   with diabetes, but no HbA1c recording *  353 (1.8) 319 (1.6)  624 (1.7) 582 (1.5)  
         
 *3FRQVXOWDWLRQIUHTXHQF\Ávisits per year), median (IQR)  1.9 (0.9 - 3.6) 4.1 (2.3 - 7.0)  0.9 (0.0 - 2.4) 2.5 (0.9 - 4.9)  
                  
         
 * in 1 year prior to MVC        
 PRVWUHFHQWUHFRUGLQJXSWR\HDUSULRUWR09&        
 Á3ULRUWR09&DQG!\HDUDIWHUVtart of computerised record.        
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Table 22: Crude and adjusted associations between involvement in motor vehicle 
crashes in THIN 255 (November 2004), by treatment category and glycosylated 
haemoglobin level 
 
The association between diabetes and MVC was considerably smaller among 
those who consulted their GP infrequently (OR=0.74, 95% CI 0.56 to 0.97) than 
among those with above-median consultation frequencies (OR=0.90, 95% CI 
0.82 to 1.00). 
Discussion 
This is the largest study of the association between diabetes and involvement in 
MVC in the UK population to date. The results suggest that once differences in 
frequency of GP consultation (and hence ascertainment bias) are taken into 
account, individuals with diabetes are less likely to be involved in MVCs than 
the general population (OR=0.78; 95% CI, 0.72 to 0.85). There was no 
Exposure  Unadjusted Odds Ratio (95% Confidence Interval) 
  
Adjusted Odds Ratio 
(95% Confidence 
Interval)* 
  
     
All diabetes 1.12 (1.04 to 1.21)  0.78 (0.72 - 0.85)  
     
%\WUHDWPHQWW\SH     
 - prescribed insulin 1.11 (0.96 to 1.28)  0.71 (0.61 - 0.83)  
 - prescribed antidiabetics 1.09 (0.96 to 1.24)  0.73 (0.64 - 0.84)  
 - untreated 1.15 (1.03 to 1.29)  0.87 (0.77 - 0.98)  
     
%\OHYHORIFRQWUROÁ     
 - good control (HbA1c < =7%) 1.19 (1.00 to 1.41)  0.81 (0.68 - 0.97)  
 - poor control (HbA1c >7%) 1.17 (1.02 to 1.35)  0.77 (0.66 - 0.90)  
 - not recorded 1.08 (0.98 to 1.19)  0.78 (0.70 - 0.86)  
          
     
* adjusted by quintile of GP consultation frequency    
LQ\HDUSULRUWR09&     
ÁPRVWUHFHQWUHFRUGLQJLQ\HDUSULRUWR09&    
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substantial difference in risk of MVC after stratification by treatment regime, or 
by level of blood glucose control. The results of the analysis stratified by 
consulting frequency suggest that any potential increased risk of MVC among 
individuals with diabetes may be largely confined to those who consult most 
frequently. These individuals are likely to be those with more severe disease, or 
those with other health problems. 
The major strength of this study is the large population available in THIN, which 
provides sufficient power to detect even a small increased risk of MVC among 
individuals with diabetes. The 2.8% prevalence of diabetes in the population is 
reassuring as it is within the range suggested by national prevalence data (98), 
allowing for the demographic characteristics of the population. This suggests 
that the method of exposure ascertainment and the recording of diabetes in 
primary care are sufficiently robust to permit the study of this condition in 
THIN. 
The major limitation of the study is, as ever, the inability of THIN records to 
effectively distinguish between drivers and other road users. Some of the 
observed reduction in risk of MVC among individuals with diabetes in the 
adjusted analysis may be due to the presence of a substantial proportion of 
individuals with diabetes who have modified their driving behaviour, refrain 
from driving, or are not permitted to drive. For this reason, the results provide a 
population level estimate of the risk of involvement in MVC among all 
individuals with diabetes, rather than the individual risk among drivers with 
diabetes. 
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Previous studies of the association between diabetes and involvement in MVCs 
have produced inconsistent results, partly due to differing sources of data, 
selections of control groups and differing treatment of potential confounding 
factors (91). The largest to date, published in 2000 and involving 66,870 drivers 
involved in MVCs in the US found a relative risk for at-fault MVCs of 1.44 
(p<0.05) among diabetic patients with unrestricted driving licenses, compared 
with the general population (84). It is unlikely that such a large effect would be 
possible in the UK population as driver behaviour varies significantly between 
countries; the results of a recent international survey suggest that drivers in the 
US are more likely to experience episodes of hypoglycaemia whilst driving than 
those in Europe, and are more likely to continue driving during an episode (88). 
In addition, European and UK licensing regulations with respect to diabetes are 
stricter than those in force in many US states, some of which impose no 
restrictions on drivers with diabetes (91). 
There has been little comparative epidemiological research into the impact of 
diabetes on MVC risk in the UK to date. A 1989 study of drivers involved in 
MVCs in Belfast found that 81 drivers with insulin-treated diabetes reported 7.9 
accidents per million miles driven, compared with 7.8 in a control population of 
76 non-diabetic drivers (83). A 2002 study in the Scottish Trauma Audit Group 
reported no increased risk of MVC leading to death or serious injury among 
individuals with diabetes (82). Both studies were based on comparatively small 
numbers of MVCs among individuals with diabetes and consequently have 
limited statistical power to detect any difference in risk of involvement in MVC 
among individuals with diabetes. The results in the THIN poplation do not 
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support these findings, possibly reflecting differences in the type and severity of 
accidents in these heterogeneous populations, or as a consequence of our 
inability to definitively identify drivers. 
Current UK driving regulations require that only individuals with insulin-
treated diabetes inform the licensing authority of their condition, and licenses 
are issued only to those with awareness of the onset of hypoglycaemia and in 
the absence of other conditions likely to impair driving performance. 
Individuals taking oral antidiabetics or controlling their condition with diet 
alone are not required to inform the licensing authority of their condition 
unless their driving may be impaired by complications of diabetes. The findings 
of this study suggest that, at population level and under the current system of 
regulation, diabetes is not associated with any increase in the risk of MVC and 
that there is little or no difference in the risk between the different treatment 
groups. On the contrary, the combined deterrent effects of the current 
regulations and raised insurance premiums may result in a lower risk of MVC 
among diabetics than in the general population. These findings do not appear to 
justify the charging of higher motor insurance premiums for drivers with 
diabetes in the current system, although it is possible that our population-level 
estimates do not reflect individual-level risks. Whether relaxation of 
restrictions on driving would result in a marked increase in MVCs is not clear.  
Conclusions 
The results of this study suggest that, once differences in consulting behaviour 
are taken into account, rates of involvement in MVCs are lower among 
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individuals with diabetes than in the general population, and that this lower 
risk is consistent between individuals receiving different treatments for 
diabetes. Further work is required to determine whether this reduction in risk 
is attributable to changes in driving behaviour arising from the current 
regulations or perceptions of increased risk among drivers with diabetes, or 
whether indeed at individual level, people with diabetes are less likely to crash.  
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8. MOTOR VEHICLE CRASHES AS A MARKER OF 
UNDIAGNOSED DISEASE ʹ A COHORT STUDY 
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Abstract 
Background. Common diseases that involve the neurological, visual and 
cardiovascular systems may impair driving ability and increase the risk of 
involvement in motor vehicle crashes (MVCs). This study tests the hypothesis 
that involvement in a MVC may predict a subsequent increased risk of being 
diagnosed with common diseases involving cardiovascular, neurological and 
visual symptoms. 
Study design and methods. Data from THIN were used to conduct a cohort 
study. The exposed cohort comprised all individuals aged over 18 years whose 
records indicated involvement in a MVC. A control cohort was selected from 
those individuals who had no recorded MVC and was matched to the MVC 
cohort by age, sex and general practice. The medical records of all participants 
were searched for subsequent diagnoses of ǡ ǯ ǡ
cataracts, glaucoma, cardiac disease, cerebrovascular disease and diabetes in 
the two years after the MVC. 
Results.  Data were obtained on 42230 individuals involved in MVCs and 
80555  ǲcontrolsǳ. After adjustment for consultation frequency, there 
was an increased incidence of a new diagnosis of cardiac disease (incidence rate 
ratio 1.20; 99% confidence intervals: 1.10 to 1.32) in the two years after the Ǥǡǯ
disease, cataracts, glaucoma, cerebrovascular disease or diabetes in the two 
years after the MVC. 
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Conclusions: Involvement in a MVC may predict subsequent development of 
cardiac disease. 
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Introduction 
The causes of Motor Vehicle Crashes (MVCs) are multifactorial, but the majority 
of incidents can be attributed to sub-optimal driving performance (99). It has 
long been recognised that a range of illnesses may contribute to impaired 
driving ability, and individuals suffering from such conditions may be subject to 
legal restrictions or prohibited from driving altogether (96). Driver impairment 
can be caused by even comparatively mild symptoms involving the 
neurological, visual and cardiovascular systems. For example, drivers with ǯ    ity to perform simple tasks of visual 
search and recognition of roadside targets even in the early stages of illness 
(100). Many diseases have a subclinical period prior to formal diagnosis when 
sensory or motor impairment may be present, leading to an increased risk of 
MVC. Involvement in a MVC may therefore constitute a sentinel event indicating 
the possible presence of an undiagnosed disease. If true, this may help in the 
earlier diagnosis of diseases that are amenable to interventions; over 50 million 
individuals are injured in MVCs each year worldwide (1), many of whom have 
contact with medical services as a result. This study uses data from THIN to 
investigate whether involvement in a MVC predicts subsequent development of 
common diseases involving visual, cardiovascular and neurological symptoms, 
excluding those (such as epilepsy) which could be directly caused by 
involvement in a crash. 
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Methods 
Study population 
Data from THIN were used to construct a cohort population. The database was 
searched to obtain details of all individuals whose records noted that they were 
involved in a first recorded MVC after 1st January 1991, at least one year after 
the start of their computerised medical record, and whilst aged 18 years or 
over. The upper age limit used in previous studies was dropped in view of the 
nature of the illnesses under investigation (see below). The date of entry into 
the study was defined as the date of the MVC. A control cohort of individuals, 
matched by age (±2 years), sex and primary care centre was randomly selected 
from those individuals with no recorded involvement in a MVC. Where possible, 
two control individuals were selected for each case. Individuals in the non-MVC 
cohort were defined as entering the study on the same date as their associated 
case, and were similarly required to have at least 1 year of computerised follow-
up data available prior to this date. 
Exposure ascertainment 
As in previous studies, SearchRC and manual inspection were used to create 
Read Term lists defining the conditions of interest. The medical and AHD table 
records of each        ǯ
disease (SearchRC term: *Parkinson*), non-alcoholic or substance abuse related 
dementias (*dement* *senil* *alzheim*), cerebrovascular disease (*cva* 
*stroke* *tia* *cerebrov*), cataracts (*cataract*), glaucoma (*glauc*), cardiac 
disease (*cardi* *angi* *heart* *ischae*) or non-gestational diabetes (using the 
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list defined previously). In each case, individuals diagnosed with the condition 
of interest on or prior to the date of entry were excluded from the population 
before analysis. The end of follow-up for each individual was defined as the date 
of diagnosis with the condition of interest, the date of death or of transfer to 
another primary care centre or two years from the date of MVC, as appropriate 
for the primary statistical analysis. The duration of two years was chosen as this 
was the median period of time data were available after the MVC. 
Frequencies of GP consultation prior to the date of MVC were calculated for 
each participant to permit adjustment for the possibility that those who visit 
their GP most regularly may be more likely to report involvement in a minor 
MVC, and that individuals in the MVC cohort may consequently be diagnosed 
with other illnesses at an earlier stage than those in the non-MVC cohort. The 
frequency of consultation was defined in the same manner as in the previous 
study. Frequencies prior to the date of MVC were used as it was considered 
likely that involvement in a MVC might temporarily or permanently affect 
consultation frequency, and that the prior level would better reflect the innate 
tendency of each individual to consult their GP for an incident illness. Postcode 
level Townsend indices were obtained where possible to allow the socio-
economic status of the MVC and non-MVC cohorts to be compared. 
Preliminary analysis      ǯ    
STATA SE version 10 for Windows Vista to compare time to diagnosis or exit in 
the MVC and non-MVC cohorts. In each case, Schoenfeld residuals were 
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calculated and the phtest postestimation command was used to test the 
assumption of proportional hazards between the two cohorts. Whilst this 
assumption was met (at the 5% significance level) for cardiac and 
cerebrovascular disease, this was not the case for the other conditions under 
investigation. Experimentation with subdividing the follow-up time did not 
allow the assumption to be met for all conditions, so the decision was taken to 
use an alternative method with less strict assumptions for all conditions for the 
sake of analytical consistency.  
Revised statistical analysis 
Poisson regression models were used to estimate crude incidence rate ratios 
(IRRs) of each condition of interest in the MVC cohort relative to the non-MVC 
cohort. A second series of analyses was conducted to estimate IRRs adjusted by 
quintile of GP consultation frequency. In both cases, 99% confidence intervals 
were calculated in view of the risk of detecting spurious associations due to the 
large number of hypotheses being tested. 
Results 
The basic demographic characteristics of the study population are given in 
Table 23. The median duration of follow-up data post MVC was 2.1 years 
(interquartile range 0.7 to 4.8). The MVC and non-MVC cohorts were similar in 
terms of both age and socioeconomic status. Individuals involved in MVCs 
consulted their GP more regularly than those in the non-MVC cohort (median 
numbers of consultations per year 2.9 and 1.6 respectively) and women 
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consulted their GP more frequently than men (3.1 versus 1.3 consultations per 
year). 
Table 23: Socio-demographic characteristics of the cohort population 
 
In the unadjusted analysis, individuals involved in MVCs were at significantly 
increased risk of being diagnosed with diabetes (IRR=1.22; 99% Confidence 
Interval CI: 1.05-1.44) and cardiac disease (IRR=1.40; 99% CI: 1.29-1.53) 
compared with those in the non-MVC cohort. There was no evidence of a       ǯ ǡ ǡ
  
Characteristic 
  Involved in MVC   Not involved in MVC   
  males females  males females  
    n =20,966 n =21,264   n =39,898 n =40,657   
         
 Age at time of MVC, median (interquartile range)  36 (27 - 49) 36 (27 - 50)  37 (28 - 49) 37 (28 - 50)  
         
 Quintile of Townsend deprivation index, n (%)        
   1st; least deprived  4644 (22.2) 5126 (24.1)  8571 (21.5) 9171 (22.6)  
   2nd  4060 (19.4) 4209 (19.8)  7193 (18.0) 7502 (18.5)  
   3rd  3953 (18.9) 4000 (18.8)  7304 (18.3) 7538 (18.5)  
   4th  3692 (17.6) 3607 (17.0)  6857 (17.2) 6872 (16.9)  
   5th; most deprived  3003 (14.3) 2629 (12.4)  6265 (15.7) 5777 (14.2)  
   not available  1614 (7.7) 1693 (8.0)  3708 (9.3) 3797 (9.3)  
         
 
Incident diagnoses up to 2 years after date of MVC, n 
(%)        
  Parkinson's disease  20 (0.1) 16 (0.1)  42 (0.1) 26 (0.1)  
  Dementia  36 (0.2) 31 (0.1)  44 (0.1) 68 (0.2)  
  Cerebrovascular disease  193 (0.9) 176 (0.8)  262 (0.7) 242 (0.6)  
  Cataract  205 (1.0) 258 (1.2)  219 (0.5) 367 (0.9)  
  Glaucoma  73 (0.3) 89 (0.4)  121 (0.3) 156 (0.4)  
  Heart disease  1950 (9.3) 2174 (10.2)  1679 (4.2) 1896 (4.7)  
  Diabetes mellitus  664 (3.2) 810 (3.8)  680 (1.7) 868 (2.1)  
         
 
GP consultation frequency* (visits per year), median 
(IQR)  
1.9 (0.9 - 
3.6) 
4.2 (2.3 - 
7.0)  
0.9 (0.0 - 
2.4) 
2.5 (0.8 - 
4.9)  
                  
 
 
* Prior to MVC and >1 year after start of computerised record. 
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cataracts, glaucoma or cerebrovascular disease between the two groups (Table 
24). 
Table 24: Association between involvement in MVCs and diagnosed disease in the 
subsequent two years 
 
Following adjustment by quintile of GP consultation frequency, involvement in 
MVCs continued to be associated with an increased incidence of cardiac disease 
(IRR=1.20; 99% CI: 1.10-1.32). The time course of this effect in the five years 
after the date of MVC is presented in Figure 1. Involvement in a MVC was no 
longer associated with an increased incidence of diabetes (IRR=1.04; 99% CI: 
0.88-1.22). Individuals involved in MVCs were at significantly decreased risk of 
being diagnosed with glaucoma (IRR=0.59; 99% CI: 0.38-0.93) and 
cerebrovascular disease (0.69; 99% CI: 0.51-0.93) compared with those in the 
control cohort. There was no evidence of a significant difference in the   ǯ ǡ     the two 
groups. 
Condition 
Unadjusted Incidence Rate 
Ratio (99% Confidence 
Interval) 
Adjusted Incidence Rate Ratio 
(99% Confidence Interval)* 
   
Dementia 0.79 (0.38-1.65) 0.67 (0.32-1.39) 
Parkinson's Disease 0.88 (0.32-2.47) 0.71 (0.25-1.99) 
Cataract(s) 1.10 (0.82-1.49) 0.89 (0.66-1.21) 
Glaucoma 0.70 (0.45-1.09) 0.59 (0.38-0.93) 
Cardiac Disease 1.40 (1.29-1.53) 1.20 (1.10-1.32) 
Cerebrovascular Disease 0.84 (0.62-1.13) 0.69 (0.51-0.93) 
Diabetes 1.22 (1.05-1.44) 1.04 (0.88-1.22) 
      
   
* Adjusted by quintile of GP consultation frequency.  
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Discussion 
This is the first study to test the hypothesis that involvement in a motor vehicle 
crash (MVC) may predict the risk of receiving a diagnosis of a common disease 
in the subsequent two years. There was a 20% excess of cardiac disease in those 
who had had a MVC compared to controls, but no difference for dementia, ǯǡǤ  
less likely be diagnosed with glaucoma or cerebrovascular disease in the two 
years following an MVC, perhaps indicating that the early symptoms of these 
conditions constitute a stronger deterrent to driving than for other diseases, or 
that these diseases are most common among those who already refrain from 
driving for other reasons. 
The major strengths of the analysis are the large size of the study population, 
which affords considerable statistical power, and the prospective nature of data 
collection in THIN. The data used in this study were collected between 1984 
and 2004 and are therefore relevant to contemporary health care systems and 
driving regulations in the UK. The cases and controls have a similar 
demographic structure as measured by the Townsend deprivation index and 
hence our results are unlikely to be a consequence of confounding by socio-
economic status. Figure 21 demonstrates that the increased incidence of cardiac 
disease in cases compared to controls is constant over time, which suggests that 
this is a true effect rather than an artefact caused by increased diagnostic pick-
up as a consequence of recent exposure to the health care system.  
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Figure 21: The incidence of cardiac disease in individuals involved in a motor 
vehicle crash compared with individuals not involved in MVCs 
 
The effect of adjusting for consulting behaviour in this analysis raises some 
interesting questions. In previous chapters, adjustments by consulting 
frequency were used to avoid or investigate the possibility of bias due to 
coincident reporting of exposure or outcome events during consultations for a 
different problem or condition. In this case, the intention was to adjust for the 
possibility that individuals who consult their GP very frequently may simply 
tend to be diagnosed with one of the outcome conditions earlier than those who 
consult infrequently, and that there may in fact be no real difference in the 
prevalence of underlying disease between individuals involved in MVCs and the 
comparison group. In practice, however, this may have been an over-
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adjustment. The Kaplan-Meier plot suggests that differences in rates of 
diagnosis of cardiovascular disease are sustained over a long period; if 
consulting behaviour was a major confounding factor, one might expect to 
observe an increasing trend towards convergence, which is not apparent in 
these data. Adjustment by consultation frequency also implicitly adjusts for the 
possibility that MVCs may be more likely to be recorded among individuals with 
poor general health (and a greater likelihood of developing the illnesses of 
interest) during attendance for other conditions. This may also be undesirable Ȃ 
if involvement in a MVC is an indicator of possible subclinical disease 
(regardless of whether this is causal or due differences in recording), adjusting 
by consultation frequency may lead to underestimation of the usefulness of 
such indicators in clinical practice. 
The main limitation of the analysis is the inability to definitively identify drivers 
in  THIN data. If, as hypothesised, the link between the MVC and the subsequent 
diagnosis of disease is causal, the presence of non-drivers in the MVC cohort 
would tent to reduce the observed effects. This provides alternative explanation 
for the absence of a positive association between involvement in an MVC and ǡǡǯǡǡ
diabetes. 
If replicated elsewhere, these findings have important implications for public 
policy. According to present trends in the United States, half of healthy 40-year-
old males will develop coronary heart disease in the future, as will one in three 
healthy 40-year-old women (101). The Screening for Heart Attack Prevention 
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and Education Task Force from the USA recommended early screening of the 
asymptomatic at-risk population (102), and the identification of new risk 
factors or precursors may help target individuals who may benefit from early 
diagnosis and intervention. Whilst the 20% increased risk of cardiac disease in 
the MVC cohort is relatively small, it is of the same order of magnitude as the 
increased risk of breast cancer among women taking hormone replacement 
therapy (103) and is therefore sufficiently large to be considered clinically 
significant. In addition, certain groups of society are difficult to identify and 
engage with health care services. All of the MVC cases in this study population 
had to make contact with the health care system to have their details of 
involvement in a MVC recorded in THIN. This provides an opportunity to 
identify and make contact with individuals who are high risk of developing 
cardiac disease, and to introduce appropriate interventions at an early stage. 
This prospective observational study is primarily hypothesis generating as it is 
not possible to identify the precise mechanism responsible for the observed 
association between involvement in a MVC and subsequent diagnosis of cardiac 
disease in these data. Potential explanations include cognitive impairment due 
to subclinical cardiovascular disease (104) or confounding by associated 
lifestyle factors such as smoking and obesity which may increase MVC risk.  The 
findings with respect to chronic diseases are generally reassuring as the 
absence of any positive association suggests that patients may refrain from 
driving soon after the onset of symptoms. Further work is required to 
investigate the association between MVC and subsequent cardiac disease in 
other datasets and to investigate the mechanisms underlying these results.  
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Conclusions 
Involvement in a MVC may be associated with the presence of sub-clinical 
cardiac disease. If this finding can be independently verified, routine screening 
by primary care practitioners of individuals involved in MVCs may aid in the 
early identification of cardiac disease. 
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Summary of findings. 
A considerable number of MVCs are recorded in THIN, but the characteristics of 
the individuals involved, and the trends in incidence over time are inconsistent 
with data from other sources. The odds of having a Body Mass Index over 30 kg 
m-2 was greater among individuals involved in MVCs than among age and sex 
matched controls (OR=1.15, 95% CI 1.03-1.29), individuals involved in MVCs 
were more likely to be past (but not current) smokers than to be ex-smokers 
(OR=1.16, 95% CI 1.02-1.32) . Current exposure to benzodiazepines (IRR=1.94, 
99% CI 1.82 Ȃ 2.32) and preparations containing opioid analgesics (Combined 
with paracetamol: IRR=2.06, 99% CI 1.84 - 2.32, Opioid alone: IRR=1.70, 99% CI 
1.39 to 2.08) was associated with an increased incidence of MVCs, as was 
longer-term use of non-benzodiazepine hypnotics (IRR=1.37, 99% CI 1.05, 
1.79), selective serotonin reuptake inhibitors (IRR=1.16, 99% CI 1.06, 1.28) and 
antihistamines (IRR=1.21, 99% CI, 1.04, 1.41). No increased incidence of MVC 
was observed with exposure to beta-blockers or tricyclic antidepressants. 
Individuals involved in MVCs were more likely to have a diagnosis of snoring 
(OR=1.91; 99%CI: 1.52 to 2.40), insomnia (OR=1.57; 99% CI: 1.45 to 1.69) or 
sleep apnoea (OR=1.68; 99%CI: 1.08 to 2.61) than age and sex matched 
controls.  Individuals involved in MVCs were (following adjustment for 
consultation frequency) less likely to have diagnosed diabetes (OR=0.78; 95% 
CI; 0.72 to 0.85) than controls, and there was no difference in risk between 
those receiving different forms of treatment. Involvement in a MVC was 
associated with an increased risk of being diagnosed with cardiac disease in the 
two years following the crash (adjusted IRR=1.20; 99% CI: 1.10 to 1.32). 
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Commentary on findings and avenues for further research 
The main advantages of using THIN to investagate factors associated with 
involvement in MVCs are the large populations available, and the wide variety 
of individual-level data recorded in primary care records. Using THIN data it is 
possible to carry out analyses which would otherwise require extremely time-
consuming and expensive prospective data collection, or for which it would not 
be feasible to collect information on a sufficiently large population. The main 
disadvantages of using THIN data are the lack of detailed information on 
individual MVCs, and poor or biased recording of some exposures Ȃ particularly 
those related to lifestyle. The work presented in this thesis illustrates these 
characteristics well. 
The results of the study investigating the impact of lifestyle factors on the risk 
of involvement in MVCs demonstrates a particular weakness of primary care 
data. Lifestyle-related exposures are poorly recorded overall, and there is 
considerable potential for ascertainment bias, as these factors are more 
important clinically among those with poorer health. Whilst the findings that 
having a high BMI and being an ex-smoker are associated with involvement in 
MVCs are plausible, the absence of an association with current smoking is not 
(especially in light of the consistency of previous published studies on this 
topic), and simply highlights the poor recording of smoking status among 
younger individuals (who are most likely to be involved in MVCs). In any case, it 
is questionable whether the previously observed findings are the result of a 
causal association as there are a number of other factors (such as a tendency 
towards risk-taking behaviour among smokers) which may confound this 
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association, and which have not been adequately addressed in the published 
literature. It is, however, difficult to conceive of a study design which could 
feasibly address these issues. 
Primary care data appear to perform better when investigating the effects of 
medications as the quality of recording of prescriptions issued is strong; most 
practice management systems have (automatically updated) formularies built 
in, simplifying the process of issuing a prescription for the practitioner, and 
issuing prescriptions through the computer systems allows the level of 
prescribing within each practice (and the budgetary consequences) to be 
monitored closely. Indeed, the computerised issue of prescriptions is mandated 
by the NHS in most circumstances. The results of the study investigating the 
impact of medication use on the incidence of MVCs demonstrates this well. The 
results are consistent with previous findings, and whilst it is not possible to 
disentangle the effects of medication use from those of the underlying 
indication in these data, in the context of the published literature on this subject 
it is likely that the findings do represent causal associations. The use of the case-
series analytical technique provides additional information about the time 
course of changes in the risk of MVC with differing durations of medication use. 
An interesting avenue for future research would be to apply this technique to 
some of the data sources used in previous studies of this topic to determine 
whether the patterns observed in THIN correctly describe these changes, and to 
more accurately estimate the magnitude of the observed effects. 
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Primary care data also work well when studying events and conditions which 
are easily entered into the management software using single, simple clinical 
codes. As discussed in Chapter 1, over 90% of consultations recorded in THIN 
carry only a single Read Term. The findings of the studies investigating the 
impact of medical conditions on the risk of MVC demonstrate this. The observed 
prevalence of diabetes in the THIN population closely approximates the 
prevalence from national surveys, and the associations between sleep disorders 
and involvement in MVCs are consistent with previous findings. Overall, it is 
likely that the findings in relation to the medical conditions investigated are 
accurate, although it is probable that the inability to distinguish drivers from 
other road users has diluted the observed effect sizes somewhat. The 
plausibility of the results relating to diabetes and sleep disorders inspires some 
confidence in the results of the analysis investigating the association between 
MVC and subsequent disease, although this work remains rather speculative. 
This issue could be addressed more definitively by screening individuals 
involved in MVCs (and an appropriate control cohort) for early signs of the 
conditions of interest, although it is likely that a large study population would 
be required to provide adequate statistical power. 
A major concern with all the analyses presented in this thesis is the possibility 
that there may be many MVCs which are not recorded as such in THIN due to 
coding of consultations according to the injuries sustained rather than their 
cause. Ongoing efforts by the NHS to improve coding of medical record data 
through defined recording quality standards and incentives (105), and 
improvements to the interfaces of practice management software packages may 
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help to improve this situation in the future, but it will be some time before these 
higher quality data comprise the majority of the research datasets. In the mean 
time, there is a clear need to develop means to retrospectively improve the 
utility of existing resources.   
As discussed in Chapter 1, the software packages used by primary care 
practitioners to maintain patient records allow the entry of text-based 
information to supplement the coded recordings. A primitive system allowing 
some of the text component of THIN records to be investigated was released 
shortly before the completion of the work for this thesis. This system lists and 
codes the most common text comments held in THIN records. Using this 
information it was possible to identify over 5,000 whiplash injuries in the MVC 
records, compared with around 100 which were coded using Read Terms. It is 
likely that this still represents an underestimate - The list of common text 
entries is only capable of identifying those which contain th ǲǳ
with no additional text or allowance for different phraseology, so any entries 
containing equivalent, but differently expressed,  ȋǤǤ ǲ-ǳǡǲ ǳǡ ǲǳǡǲǳǤȌve 
been missed. It is also interesting to note that the list of common text entries   ǲǳȋ  ǲ ǳȌ
lending credence to the earlier suggestion that the low incidence of MVCs in 
THIN compared with national statistics may be a consequence of a large 
number of crashes being Read coded only according to the injury sustained. The 
extent to which the absence of these additional recordings from the datasets 
used in this thesis may have biased or otherwise affected the results is 
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unknown. Another worthwhile avenue for future research would be to 
investigate whether these text data could be converted to Read Terms. If this 
were possible, it would enable more robust analyses of the impact of 
medication use and medical conditions of the risk of MVCs (and other accidents 
or causes of injury) to be carried out without considerable additional work. In 
addition, such data would increase the populations available for study, 
permitting investigation of rarer exposures and the calculation of more accurate 
estimates. Access to such data might also permit the use of primary care records 
to accurately quantify the incidence of MVCs at population level and allow more 
meaningful comparisons with data from other sources to be made. 
In conclusion, it is clear that there is considerable uncertainty as to the accuracy 
of many of the findings presented in this thesis, although it is likely that the 
analyses of the associations between medication use and medical conditions 
and MVCs are representative of the direction of any true effects, if not the 
magnitude. The studies presented demonstrate important strengths and 
weaknesses of using primary care data for research, and describe designs and 
analytical techniques which could be used to effectively address the issues 
investigated in more appropriate datasets or in improved primary care datasets 
which may become available in the future. 
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Latest approved protocol 
Smoking and Road Traffic Accidents: A Case Control Study 
Department of Respiratory Medicine 
University of Nottingham 
Nottingham City Hospital 
Hucknall Rd 
Nottingham 
NG5 1PB 
 
Background 
It is well recognised that smoking is a cause of many health problems, especially 
respiratory diseases, cardiovascular disease, and several forms of cancer. In 
1990 tobacco and road traffic accidents (RTA) were the first and eighth highest 
causes of death causing 400, 000 deaths (19% to total) and 25, 000 deaths (1% 
of total) respectively, in an assessment of environmental causes of mortality in 
the United States (1). It is important to understand any potentially reversible 
risk factors which contribute to the complex aetiology of RTA as these are a 
significant cause of death in young people, in whom 40% of all deaths were 
caused by motor vehicles (1). 
It is biologically plausible that car drivers who smoke will have an increased 
risk of RTAs compared to those who do not smoke, as a consequence of the 
decreased concentration on the task of driving while lighting and smoking a 
cigarette, smoking related medical conditions and direct toxicity from inhaling 
the cigarette fumes. Very few studies have directly addressed this question, as it 
is methodologically difficult and few datasets possess sufficient data to do so. As 
a consequence the majority of the literature consists of small studies which are 
 160 
 
vulnerable to bias. A case-control study from Canada demonstrated that 
smokers have a 50% excess risk of having been at fault for an RTA compared to 
non-smokers (2). Smokers in a cohort study of 80 000 adults from the USA have 
a risk of 1.83 times that of non-smokers of having a RTA over a five year period 
(3). Similar associations have been shown for using a mobile phone when 
driving and increased risk of RTA (4). This activity is now illegal in England and 
Wales. To our knowledge, there have been no studies of the risk of smoking on 
RTA in England and Wales, or in any countries which drive on the left hand side 
of the road. If those who smoke do have a 50% excess risk of a RTA then the 
estimated societal cost in terms of property damage, injuries, deaths and health 
care costs in 1988 has been estimated to be over seven billion dollars Sacks (5). 
We propose a case-control study to investigate the risk of smoking on road 
traffic accidents. If this demonstrates that, in an English population, smoking is 
a risk factor for road traffic accidents, we will pursue this area of research using 
quantitative and qualitative research methodology. The ultimate aim is to 
develop and evaluate public health interventions which will reduce the impact 
of this problem. 
As the usage of medication with sedative properties (benzodiazepines, anti-
histamines, other sleeping tablets) and other drugs which are known to impair 
performance such as beta-blockers may also reduce concentration while 
driving, we will also use this opportunity to assess the effect of the regular 
usage of these medications on the risk of having a RTA. 
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We also propose to use the study population to determine whether having a 
RTA may be an early indicator of undiagnosed or subclinical disease, and to 
identify which existing medical conditions may increase the risk of RTA. 
Methods 
Study population 
The THIN Research Database is a longitudinal database of general practice 
records established in 1987 that covers nearly 4 million patients in England and 
Wales. It is not possible to identify individuals from this database. Over this 
period, a provision search has revealed that 86 361 patients have been coded as 
having had a RTA. We aim to randomly select 10 000 of these along with 2 
controls for each case. Controls will not have had a RTA in the time period 
covered by the study and will be matched for gender, age and general 
practitioner. Data on potential confounding factors such as alcohol intake, socio-
economic status, epilepsy, as well as factors that may be confounding or on the 
causal pathway such as a diagnosis of ischaemic heart disease, cerebro-vascular 
disease or diabetes will be collected. 
Statistical analysis 
Statistical analysis will use logistic regression to ascertain the effect of smoking 
status (never, ex-smoker, current smoker) on the risk of being involved in an 
RTA. We will also proceed to see if there is a dose-response relationship 
between the number of daily cigarettes consumed and the risk of an RTA. If an 
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effect is seen for smoking on the risk of RTA, this will be explored for potential 
confounding factors by adjusting for these. As the consumption of alcohol is an 
important confounding factor, we will repeat the analysis using a limited 
subpopulation of those who do not drink alcohol. The same analytical approach 
will be used to assess the effect of sedative medication and other drugs known 
to impair performance on the risk of having a RTA. 
We will use cohort methods to compare the rates of subsequent diagnosis of 
conditions which might impair driving performance including dementia, ǯ ǡ ǡ      
cases and controls in the time period after the date of accident. We will also use 
case-control methods to investigate the impact of conditions diagnosed prior to 
the date of accident. 
Reference List 
(1)  McGinnis J, Foege W. Actual causes of death in the United States. JAMA 
1993; 270:2207-2212. 
(2)  Brison J. Risk of automobile accidents in cigarette smokers. Can J Pub 
Health 1990; 81:102-106. 
(3)  Leistikow B, Martin B, Samuels S. Injury death excesses in smokers: a 
1990-95 United States national cohort study. Injury prevention 2000; 6:277-
280. 
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(4)  Redelmeier D, Tibshirani R. Association between cellular-telephone calls 
and motor vehicle collisions. New Eng J Med 1997; 336:453-458. 
(5)  Sacks J, Nelson D. Smoking and injuries: An overview. Preventive 
Medicine 1994; 23:515-520. 
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Appendix II: SearchRC Source code 
Note: SearchRC is installed as an .ado file. The data file containing the Read 
Term dictionary must comprise two variables  ǲmǳ ȋ
the Read Term Code)  ǲǳ ȋ     
format). 
program define searchrc 
 
 
 
 
  version 9.0 
  syntax anything [,csen keepcat keeptree current file(string asis)] 
  
  capture {  
   if "`current'"!="current" { 
    use `file', clear 
   } 
 
   gen _keep=0 
   gen _testdes=trim(description) 
    
   foreach a of local anything { 
 
    if strpos("`a'","*")==0 & "`csen'"=="csen" { 
     replace _keep=1 if _testdes=="`a'" 
    } 
 
    if strpos("`a'","*")==0 & "`csen'"!="csen" { 
     replace _keep=1 if lower(_testdes)==lower("`a'") 
    } 
 
    if strpos("`a'","*")==1 & strpos(reverse("`a'"),"*")==1 { 
     if "`csen'"=="csen" { 
      replace _keep=1 if 
strpos(_testdes,substr("`a'",2,length("`a'")-2))!=0 
     } 
     else { 
      replace _keep=1 if 
strpos(lower(_testdes),lower(substr("`a'",2,length("`a'")-2)))!=0 
     } 
    } 
    
    if strpos("`a'","*")==1 & strpos(reverse("`a'"),"*")!=1 { 
    
     if "`csen'"=="csen" { 
      replace _keep=1 if 
strpos(reverse(_testdes),reverse(substr("`a'",2,length("`a'")-1))))==1 
     } 
     else { 
      replace _keep=1 if 
strpos(reverse(lower(_testdes)),reverse(lower(substr("`a'",2,length("`a'")-1))))==1 
  
     } 
    } 
 
    if strpos("`a'","*")!=1 & strpos(reverse("`a'"),"*")==1 { 
     if "`csen'"=="csen" { 
      replace _keep=1 if 
strpos(_testdes,substr("`a'",2,length("`a'")-1))==1 
     } 
     else { 
      replace _keep=1 if 
strpos(lower(_testdes),lower(substr("`a'",2,length("`a'")-1)))==1 
  
     } 
    } 
  
 
   } 
  
   gen int _kcn=0 
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   sort _keep 
   by _keep: replace _kcn=_n if _keep==1 
   gsort -_kcn 
   local total=_kcn[1] 
   local runner=1 
   gen lv=strpos(medcode,".") 
   if "`keepcat'"=="keepcat" { 
  
    while `runner'<=`total' { 
     gsort -_kcn 
     display medcode[`runner'] 
     local level=strpos(medcode[`runner'],".") 
     if `level'>3 { 
      replace _keep=1 if 
strpos(medcode,substr(medcode[`runner'],1,`level'-2))==1 &lv==`level' 
     } 
     if `level'==0 { 
      replace _keep=1 if 
strpos(medcode,substr(medcode[`runner'],1,4))==1 &lv==0 
     } 
     local latest=`runner' 
     local runner=`latest'+1 
    } 
  
   } 
  
   if "`keeptree'"=="keeptree" { 
    while `runner'<=`total' { 
     gsort -_kcn 
     local level=strpos(medcode[`runner'],".") 
     if `level'==5 { 
      local 
match=substr(medcode[`runner'],1,`level'-2)+".." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
      local 
match=substr(medcode[`runner'],1,`level'-3)+"..." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
      local 
match=substr(medcode[`runner'],1,`level'-4)+"...." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
     } 
     if `level'==4 { 
      local 
match=substr(medcode[`runner'],1,`level'-2)+"..." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
      local 
match=substr(medcode[`runner'],1,`level'-3)+"...." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
     } 
  
     if `level'==3 { 
      local 
match=substr(medcode[`runner'],1,`level'-2)+"...." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
     
     } 
     if `level'==0 { 
      local match=substr(medcode[`runner'],1,4)+"." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
      local match=substr(medcode[`runner'],1,3)+".." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
      local 
match=substr(medcode[`runner'],1,2)+"..." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
      local 
match=substr(medcode[`runner'],1,1)+"...." 
      replace _keep=1 if 
"`match'"==substr(medcode,1,5) 
     } 
     local latest=`runner' 
     local runner=`latest'+1 
    } 
   } 
   keep if _keep==1 
   keep medcode description 
   sort medcode 
 } 
 display "Found `total' Read descriptions containing search term(s)" 
 local extra=string(_N-`total') 
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 display "Retained `extra' additional codes from same category or tree" 
 
end 
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Appendix III: List of Postgraduate Training Courses Attended 
1. Exploiting the Power of MS Word     2 credits 
2. Preparing and Presenting an Effective CV    2 credits 
3. Visual Basic for Applications      2 credits 
4. Finishing Your Thesis and Preparing for the Viva   2 credits 
5. Getting Going on Your Thesis and Getting Your Work Published 2 credits 
6. Building a Bibliography 2005 (an Online Learning Course)  1 credit 
7. Clinical Trials 1 & 2       2 credits 
8. Scientific Abstracts and First Year Reports    1 credit 
9. Critical Analysis of Scientific Literature Coursework   2 credits 
10. Postgraduates who Teach: Communication Skills   1 credit 
11. Faculty Postgraduate Research Forum     3 credits 
Total 20 
credits 
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Appendix IV: List of Abbreviations 
 
AHD  Additional Health Details 
BMI  Body Mass Index 
bn  Billion - short scale 
CI  Confidence Interval 
DfT  The United Kingdom Department for Transport 
e.g.  Exempli gratia 
GATE  General Architecture for Text Engineering 
GP  General Practitioner 
GPRD  The General Practice Research Database 
HbA1c  Glycosylated Haemoglobin level 
HES  Hospital Episode Statistics 
i.e.  Id est 
ICD  International Classification of Diseases 
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IMD2000 Indices of Multiple Deprivation 2000 
IRR  Incidence Rate Ratio 
IT  Information Technology 
kg  Kilogram 
m  Metre 
MRC  The Medical Research Council 
MVC  Motor Vehicle Crash 
MVTA  Motor Vehicle Traffic Accident 
N.B.  Nota bene 
NHS  The United Kingdom National Health Service 
NOS  The Newcastle Ottawa Scale 
OR  Odds Ratio 
OSA  Obstructive Sleep Apnoea Syndrome 
pp  Pages 
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PPA  The Prescription Pricing Authority 
PPI  Proton Pump Inhibitor 
PVI  Postcode Variable Indicators 
RTA  Road Traffic Accident 
SE  Standard Error 
SSRI  Selective Serotonin Reuptake Inhibitor 
THIN  The Health Improvement Network 
UK  The United Kingdom of Great Britain and Northern Ireland 
US  The United States of America 
y/n  Yes or no  
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